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ABSTRACT 
 
 
Vitamin D metabolites regulate calcium absorption in the intestines through 
activation of the vitamin D receptor (VDR) and resulting in increased expression of 
calcium-associated proteins. Presently, it is thought that vitamin D metabolizes into a 
hormonal form, 1,25-dihydroxyvitamin D (1,25D), and the hormone then circulates via 
blood to the duodenum to stimulate calcium absorption. Recently, Koszewski et al. 
proposed that delivery of the hormone occurs via digestive passage rather than by the 
blood (Koszewski et al., 2012). Growing evidence has suggested, instead, that the 
hormonal precursor, 25-hydroxyvitamin D (25D), may have functional activity by either 
providing substrate for local hormonal production or by agonistically stimulating a 
response. In addition, the liver is recognized to produce and excrete both 25D and the 
glucuronide form, 25D-Gluc, in bile. The hypothesis guiding the present dissertation is 
that both 25D and 25D-Gluc may have hormonal effects in the intestine when delivered 
by way of digesta.  
The following dissertation investigates the delivery and mechanism driving 
intestinal responses by these metabolites. Acute dosing of vitamin D metabolites, 25D 
and 1,25D, as well as their respective glucuronide conjugated derivatives, in vitamin D-
normal mice was used to assess intestinal responses in vivo. Assays performed in cell 
culture were used to examine mechanisms of action. Responses to the metabolites both in 
vivo and in vitro were evaluated by measuring Cyp24 mRNA, an early and robust 
indicator of the VDR-mediated response. These assessments of Cyp24 were analyzed 
x 
quantitatively by PCR and qualitatively by RNAscope, a recently developed RNA in situ 
hybridization technique. Results from these studies suggest that the vitamin D-mediated 
response is limited to intestinal epithelial cells nearest the luminal interior in both the 
duodenum and colon. Orally administered 25D was shown to elicit a response in the 
duodenum through agonistic binding and activity. Lastly, both oral and subcutaneous 
25D-Gluc exhibited hormonal actions in the colon, but not the duodenum. The overall 
conclusion drawn from this dissertation is that 25D and its glucuronide conjugate are 
meaningful participants in regulating the VDR-mediated response in the intestines.  
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CHAPTER 1.    GENERAL INTRODUCTION 
Introduction and Justification 
Vitamin D-mediated intestinal calcium absorption is essential to the formation and 
continuous remodeling of bones. Stimulation of the intestine is thought to occur by renal 
synthesis of the hormone, 1,25-dihydroxyvitamin D (1,25D), and its transport to the 
basolateral membrane of the intestinal duodenum. However, surgical removal of the colon 
and/or placement of an ileostomy proximal to the colon leads to difficulties managing 
calcium absorption and signify a vital role for the colon in calcium absorption (1). 
Furthermore, in the Roux-en-Y gastric bypass procedure it is common for the rate of calcium 
absorption to be impaired despite increases in both parathyroid hormone and 1,25D (2,3). 
Management of these medical scenarios has been difficult and challenge the conventional 
understanding of vitamin D-mediated intestinal calcium absorption (4,5). 
The objectives pursued in the present dissertation demonstrate a potential alternate 
pathway for vitamin D metabolites to stimulate the intestines. Our efforts in understanding 
the precise mechanism of vitamin D-dependent calcium absorption may lead to new 
strategies to manage calcium absorption, particularly following intestinal surgical alterations. 
 
Research Objectives 
The Goff Laboratory had previously investigated the action of 1,25D-glucuronic acid 
(1,25D-Gluc) and found that it stimulates the vitamin D-mediated response in the colon. 
Interestingly, Goff and colleagues had noted a peculiar aspect of 1,25D: that increasing the 
concentration of 1,25D in the serum did not necessarily induce the vitamin D-mediated 
response in the colon, even though the colon demonstrated the ability to respond. My first 
2 
objective was to identify the cells and tissue regions that produce the vitamin D-mediated 
response in both the duodenum and the colon. Importantly, this project utilized a new RNA 
in situ hybridization technique that has immense potential in research for vitamin D and other 
steroid hormones that modulate transcription. The research for this objective was 
fundamental to influencing the decisions and justifications made for the following objectives.  
25-Hydroxyvitamin D is most often bound to proteins, but if ingested, such proteins 
would likely be denatured by digestion. Any 25D consumed would be unbound to proteins. 
Most animal-based products contain small around 0.5 ng/g of 25-hydroxyvitamin D, but 
consuming this amount is deemed insignificant in improving the vitamin D status of an 
individual (6). Evidence has suggested that 25D could be a substrate for autocrine and/or 
paracrine action within the intestine (7,8); however, no research has considered the effect of 
consumed 25D on stimulating the vitamin D hormonal response prior to absorption into the 
bloodstream. For my second objective, we pursued the hypothesis that orally consumed 25D 
could result in a hormonal response in the intestine by way of autocrine action. We evaluated 
its action in orally-treated mice and assessed the mechanism in cell culture assays. 
Recently, the vitamin D metabolite, 25D-glucuronic acid (25D-Gluc), was found to 
be produced by the liver and present in human blood and bile (9). The Goff Laboratory had 
already explored the action of 1,25D-Gluc, thus, we could anticipate an effect in the colon. 
Based on the evidence that oral 25D had hormonal effects in the duodenum, we generated the 
hypothesis that this 25D-Gluc in humans would stimulate a hormonal response in the colons 
similar to that of 1,25D-Gluc. This objective was tested in cell culture and a mouse model. 
We then tested the concept that 25D-Gluc must be secreted into the digesta in order to elicit a 
response in the colon by performing surgical ligations in mice.  
3 
Dissertation Organization 
The present dissertation is organized into chapters focused on the actions of vitamin 
D metabolites on the intestines. Chapter 2 reviews previous and current literature on vitamin 
D and is pertinent to understanding the background and significance of the following 
chapters. The following three chapters contain manuscripts of journal articles that have been 
or are intended to be submitted for publication. The content of Chapter 3, “Localization of 
the 1,25-dihydroxyvitamin D-mediated response in intestines of mice,” has been published in 
the Journal of Steroid Biochemistry and Molecular Biology, a peer reviewed journal. Chapter 
4, “The agonistic action of oral 25-hydroxyvitamin D in the duodenum of mice and as 
modeled in vitro” has been prepared for submission to the Journal of Nutrition, a peer 
reviewed journal, and discusses the action of 25D in the duodenum. Chapter 5, “The role of 
25-hydroxyvitamin D-3-glucuronic acid on colon gene expression” is a manuscript in 
preparation for submission to a peer reviewed journal to be determined and investigates the 
action of 25D-Gluc in the colon. An overall summery and conclusion is discussed in Chapter 
6 along with applications of the present research that propose contributions toward the 
general knowledge of science.  
 
References 
1.  Hylander E, Ladefoged K, Jarnum S. Calcium Absorption after Intestinal Resection. The 
Importance of a Preserved Colon. Scand J Gastroenterol. 1990; 25(7): 705-710. 
2.  Schafer AL. Vitamin D and intestinal calcium transport after bariatric surgery. J Steroid 
Biochem Mol Biol. 2017 ;173(2016): 202-210.  
3.  Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C. Endocrine and 
nutritional management of the post-bariatric surgery patient: An endocrine society clinical 
practice guideline. J Clin Endocrinol Metab. 2010; 95(11): 4823-4843.  
  
4 
4.  Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, Stewart L, Rogers SJ, 
Carter JT, Posselt AM, Shoback DM, Sellmeyer DE. Intestinal calcium absorption decreases 
dramatically after gastric bypass surgery despite optimization of vitamin D status. J Bone 
Miner Res. 2015; 30(8): 1377-1385.  
5.  Pietras SM, Holick MF. Refractory hypocalcemia following near-total thyroidectomy in a 
patient with a prior roux-en-y gastric bypass. Obes Surg. 2009; 19(4): 524-526.  
6. Ovesen L, Brot C, Jakobsen J. Food contents and biological activity of 25-hydroxyvitamin D: 
A vitamin D metabolite to be reckoned with? Ann Nutr Metab. 2003; 47(3-4): 107-113. 
7.  Balesaria S, Sangha S, Walters JRF. Human duodenum responses to vitamin D metabolites of 
TRPV6 and other genes involved in calcium absorption. Am J Physiol Liver Physiol. 2009; 
297(6): G1193-G1197.  
8.  Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M. 
Extrarenal Expression of 25-Hydroxyvitamin D3 -1 a-Hydroxylase*. J Clin Endocrinol Metab. 
2001; 86(2): 888-894. 
9.  Wang Z, Wong T, Hashizume T, Dickmann LZ, Scian M, Koszewski NJ, Goff JP, Horst RL, 
Chaudhry AS, Schuetz EG, Thummel KE. Human UGT1A4 and UGT1A3 conjugate 25-
hydroxyvitamin D3: Metabolite structure, kinetics, inducibility, and interindividual variability. 
Endocrinology. 2014; 155(6): 2052-2063  
 
 
 
5 
CHAPTER 2.    LITERATURE REVIEW ON VITAMIN D 
Vitamin D  
Introduction 
Vitamin D provides the metabolic tools essential for maintaining and balancing 
calcium in all living animals. Without sufficient vitamin D, humans and animals suffer 
calcium deficits that affect bone strength and development. Calcium deficits then progress 
into the debilitating bone diseases such as rickets and osteoporosis. Even a modest vitamin D 
insufficiency has negative health effects that can evolve into the onset of autoimmune 
disorders, type 2 diabetes mellites, and some cancers (1–4). While vitamin D is produced 
naturally by sunlight exposure to skin, it becomes a dietary necessity for several months of 
the year when adequate sunlight diminishes. Despite the current efforts in promoting vitamin 
D, deficiencies and insufficiencies remain epidemic in developed nations.  
 
Metabolic action 
The function of vitamin D is to provide a substrate pool for its endocrinal metabolite 
(5). Endogenous synthesis of vitamin D occurs from the ultraviolet-induced ring-opening of 
7-dehydrocholesterol, an intermediate common with the cholesterol biosynthesis pathway. 
The resulting cis-structured molecule then isomerizes into a trans configuration; yielding 
cholecalciferol, vitamin D3, or simply vitamin D (6–8).  
Vitamin D is transported to the liver bound to vitamin D-binding protein (DBP) and 
integrated with very low-density lipoproteins (9,10). After endocytosis into the liver, vitamin 
D undergoes hydroxylation at the 25-carbon to form 25-hydroxyvitamin D (25D). This 
hydroxylation step initially was thought to be done by mitochondrial cytochrome P450 
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family 27, subfamily A, member 1 (Cyp27a1), but microsomal cytochrome P450 family 2, 
subfamily R, member 1 (Cyp2R1) is evidently responsible for the greatest impact on 25D 
synthesis and the concentration of serum 25D (11–13). The hepatic 25D product then is 
released into the blood where approximately 85% is bound to DBP and 15% is bound to 
albumin and lipoproteins (14). Measurement of serum 25D, also referred to as the “vitamin D 
status,” is generally 50-250 nmol/L (20-100 ng/mL) (15–17). 
25-Hydroxyvitamin D is the intended substrate for renal 1α,25-dihydroxyvitamin D 
(1,25D) synthesis. The renal proximal tubules take up 25D when it is bound to DBP via the 
megalin/cubulin-mediated endocytosis mechanism (18,19). The mitochondrial 1α-
hydroxylase, also referred to by its gene name cytochrome P450 family 27, subfamily B, 
member 1 (Cyp27b1), then forms 1,25D and releases it into circulation as an endocrinal 
steroid hormone. In circulation, 1,25D is maintained in the concentration range of 70-200 
pmol/L (30-84 pg/mL; 20,21). Low serum calcium indirectly increases 1,25D by stimulating 
parathyroid hormone secretion to induce expression of Cyp27b1 (22,23). Conversely, FGF23 
(in response to excess phosphate) and 1,25D (in a negative feedback manner) downregulate 
Cyp27b1 expression to lessen the production of 1,25D (24,25). 
Once 1,25D reaches the cytosol of the target cell, it binds to VDR in the hydrophobic 
pocket of the ligand-binding domain. Binding induces a conformational change of VDR that 
enables translocation to the nucleus and exposes an interface for heterodimerization with the 
retinoid x receptor (RXR; 26–29). The zinc finger DNA-binding domains of the VDR-RXR 
dimer then locate the vitamin D response element (VDRE) sequence and recruit assembly of 
histone modification proteins and mediator complex proteins (26,28,30). The protein 
assembly then recruits the RNA polymerase for initiation of transcription. Through 
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chromatin-immunoprecipitation and sequencing (ChIP-seq) assays, the location of these 
VDREs relative to the transcription start site varies greatly, with most appearing within 30 kb 
upstream of the transcription start site and extending out to desert regions beyond 400 kb 
(30). 
 
Vitamin D signaling in the intestines 
The function of 1,25D for the intestines is to increase proteins that will increase 
calcium uptake from the diet. Ligand-activated VDR promotes transcription of transient 
receptor potential cation channel subfamily V, member 6 (TRPV6), calbindin-D9k 
(CaBP9K), plasma membrane calcium-ATPase isoform 1, variant b (PMCA1), sodium-
calcium exchanger 1 (NCX), and cytochrome P450 family 24, subfamily A, member 1 
(Cyp24; 31–33). These proteins facilitate transport of calcium ions from the lumen of the 
intestine, through the epithelial cell, and into circulation, and have been reviewed in detail 
numerous times (Figure 1.1; 34–41). Below are brief descriptions of each protein and its role 
in transcellular transport of calcium in the intestines. 
TRPV6 is a tetrameric protein on the apical membrane of the intestinal epithelium 
that selectively transports Ca2+ through a gated channel into the cytosol (42,43). Expression 
of TRPV6 is sensitive to 1,25D stimulation; however, it is likely not the sole transporter 
involved in 1,25D-mediated intestinal calcium absorption (43–45). Additional calcium 
channels, TRPV5 and Cav1.3, have been suggested; yet, their level of involvement remains to 
be determined (37–39). 
CaBP9K is a cytosolic calcium-binding protein that carries Ca2+ from the apical to 
the basolateral membrane (46). Expression of CaBP9K is sensitive to 1,25D stimulation 
(31,47), but its abundance is generally greatest in the duodenum and diminishing along the 
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intestinal tract with the lowest expression in the distal regions (48).  Interestingly, the 
knocking-out CaBP9K in a mouse model had little impact on phenotype and calcium 
absorption, suggesting that CaBP9K is a redundant protein and that other calcium binding 
carriers are involved (49). A double knock-out model of both TRPV6 and CaBP9K did have 
a synergistic impairment on calcium absorption, demonstrating a coordination of TRPV6 
with CaBP9K (45,50).   
PMCA1 is a basolateral membrane protein involved in the transfer of cytosolic 
calcium across the basolateral membrane and into circulation. PMCA1 has ATPase activity 
that couples hydrolysis of ATP with the transport of calcium against a concentration gradient. 
At one point, Walters et al. found that the abundance of duodenal PMCA1 was not dependent 
on 1,25D stimulation (47). However, that claim was later refuted by mRNA analyses and 
PMCA1 was confirmed to be upregulated by 1,25D (32,51). Structural data have revealed 
that PMCA1 contains an autoinhibitory subunit that is blocked by cytosolic calmodulin (52). 
Docking of calmodulin onto PMCA1 activates the calcium channel. The specificity of the 
autoinhibitory subunit is not well defined; thus, it is possible that other calcium-binding 
proteins, such as CaBP9K, could participate in activating calcium transport. Activity of 
PMCA1 is also dependent on the presence of cofactors whose relationships to vitamin D are 
uncertain. One of these proteins, 4.1R, recently has been identified and may also be mediated 
by 1,25D (52,53). Regardless, the activity and regulation of PMCA1 are still being 
researched.  
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NCX is an additional basolateral membrane transporter that uses the binding of 
sodium ions to aid in extruding calcium into circulation (54). Evidence suggests that NCX is 
responsive to 1,25D-stimulation and involved in intestinal calcium absorption, but to a lesser 
extent than is PMCA1 (33,38,55). Research on NCX with respect to 1,25D-mediated calcium 
absorption is rather new and not yet comprehensive. 
CYP24 hydroxylates 1,25D and disables its action as part of a negative feedback 
system (13,56,57). It does not participate in calcium absorption. Conveniently, the promoter 
sequence upstream of the Cyp24 gene contains two VDREs near the transcription start site. 
As a result, Cyp24 is very sensitive to 1,25D-stimulation and increases expression readily 
and robustly, making it a strong indicator of the 1,25D-mediated response. 
While transcellular absorption of calcium is the most researched mechanism for 
1,25D-mediated calcium absorption, it is not the only pathway. Passive paracellular 
absorption of calcium from the lumen of the intestines directly into circulation does occur in 
the intestine. This passive route is facilitated by 1,25D through decreased expression of 
extracellular claudin proteins that regulate the tight junction space between cells and allow 
passive absorption to proceed (58–60). 
Signaling to the intestinal cells largely occurs through the upregulation of the above 
proteins, but cells also demonstrate an immediate response to 1,25D. Early studies had found 
that the rate of calcium absorption increases within minutes of receiving a bolus of 1,25D 
(61,62). Emerging research has found the membrane protein, protein disulfide isomerase 
family A, member 3 (Pdia3), is a receptor for 1,25D and initiates a signaling cascade to 
activate protein kinase C (63–65). This pathway may justify previous observations on a rapid 
response in the intestine and warrants further research. 
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Intestinal location of the 1,25-dihydroxyvitamin D-mediated response 
The cellular target of 1,25D within the intestine has not been well-defined, but can be 
predicted on the basis of the location of VDR. Immunohistochemical assays of intestinal 
tissues for VDR have shown that the cellular response is primarily located in the epithelial 
layer. In multiple chromogenic detection assays, VDR consistently appeared in crypt regions 
of the duodenal architecture and diminished along the villi with much less apparent in the 
tips (66–69). Colons were shown with similar localizations, where the VDR appeared with 
greatest density deep within the crypts. One group used fluorescence labeling, but found 
VDR evenly distributed along the entire epithelial layer, from crypt to tip in both the 
duodenum and the colon (70). 
Proteins from activated VDR also have been assessed by immunohistochemistry. 
Colston et al. stained the human duodenum for alkaline phosphatase and found that the 
protein appeared most abundantly in the tips of the villi and little appeared in the crypt 
regions (66). Similarly, Sidler-Lauff et al. stained for CaBP9K in goat duodena and also 
found the abundance of CaBP9K in the tip regions (68). These data do not agree with the 
evidence presented on the intestinal locations of VDR. One must consider that just because a 
gene is transcribed does not necessarily lead to an increased abundance of its respective 
protein.  
As of yet, the controversy remains as to which cells are the intended targets of 1,25D. 
All immunohistochemistry studies, however, agree that the submucosa and muscular layer 
are not expected to respond to 1,25D, and all studies agree that the response occurs in the 
epithelial cells. 
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Vitamin D-mediated calcium absorption in the colon 
The colon expresses proteins involved in 1,25D-mediated calcium absorption; yet, 
calcium absorption by the colon has been largely neglected (71–73). In vitro studies found 
that colon segments could absorb more calcium following treatment with 1,25D (74). The 
ability of the in vivo colon to actively absorb calcium in response to 1,25D stimulation was 
described in a 1984 publication by Grinstead and colleagues (75). In this study, human 
subjects were given 1,25D or placebo orally for one week and then a calcium radioisotope 
was infused into the distal ileum and colon. The resulting flux of calcium radioisotope from 
the colon into the serum increased significantly with oral 1,25D-treatment. The vital 
importance of the colon was later identified among intestinal resection patients, for whom a 
portion of the colon was needed to remain intact in order to maintain adequate calcium 
absorption (76). 
Recent studies using genetic manipulations of VDR add emphasis to the importance 
of calcium absorption by the colon (50). VDR-null mice exhibit a phenotype that is unable to 
respond to 1,25D and suffer rickets-like symptoms with severe bone and calcium deficits 
(77,78). Incredibly, Dhawan and colleagues rescued much of the deficits by re-introducing 
transgenic VDR into just the distal intestine of these VDR-null mice (79). In the reverse 
situation, knocking out VDR only in the distal intestine of normal mice caused impairments 
in bone development and increased duodenal compensation for calcium absorption (80). 
These studies demonstrate the importance of 1,25D-dependent calcium absorption in the 
distal intestine, particularly with respect to bone development and remodeling (50). 
Impairments in calcium absorption lead to a slow, steady decline in calcium 
homeostasis as the body removes calcified bone in order to maintain plasma calcium 
concentrations. These discrete, subclinical signs of negative calcium balance can persist 
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undetected for many years and can lead to secondary hyperparathyroidism, metabolic bone 
disease, and clinical hypocalcemia. Mice that do not express intestinal VDR in either the 
small or large intestine cannot regulate dietary calcium absorption from renal 1,25D 
signaling (81). Although the 8-week-old mice did not succumb to hypocalcemia, they did 
exhibit increased circulating 1,25D, but with decreased expression of intestinal calcium 
channels, impaired calcium absorption, increased parathyroid hormone, poorly mineralized 
bones, and spontaneous fractures. Thus, it is evident that the 1,25D-stimulation of the colon 
is vital for calcium absorption and homeostasis. 
 
25-Hydroxyvitamin D 
25-Hydroxyvitamin D was discovered as an anti-rachitic factor with 5-fold greater 
potency than vitamin D. Initially, it was considered the active metabolite of vitamin D 
(82,83); however, the discovery of 1,25D changed the focus of vitamin D research away 
from 25D (84,85). Because 25D was found to be carried by DBP in blood, it was assumed to 
be sequestered from any activity at physiological conditions (14,86,87). The functional 
importance of 25D, therefore, was limited to simply being the precursor to 1,25D (17,88,89). 
As a result, many studies evaluated 25D only as a contributor to serum vitamin D status, yet 
25D has been frequently analyzed because its abundance allows for more cost-effective 
methods for measurement. Given the assigned role of pre-hormone, food analyses revealed 
concentrations of 25D that were deemed insignificant.  
A renewed interest has recently sparked on the functional capacity of 25D. This 
interest is based on the finding of extra-renal 1α-hydroxylase in tissues such as placenta, 
macrophage, parathyroid gland, and, of most pertinence, the intestines (32,72,73,90–93). The 
presence of the 1α-hydroxylase in the intestine suggests that 25D could feasibly be 
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hydroxylated into 1,25D within the cell and exert an autocrine or paracrine action locally. 
However, entry of 25D that is largely bound to BDP posed a problem. With these findings, 
an interest in measuring free 25D has emerged with the hopes that 25D may participate in 
local hormonal actions. 
25-Hydroxyvitamin D also can bind to VDR to initiate its hormonal response 
(26,94,95). This effect has been observed in vitro with various cancer and primary cell lines 
and by using various forms of impairment to the hydroxylase including knock-out, knock-
down, RNA interference, and competitive inhibition (96–99). The agonistic action of 25D, 
however, remained at or above physiological concentrations of 100 nM in all of those 
experiments. Because the actual free-25D is only a fraction of the amount needed to 
stimulate VDR, this hypothesis would be considered impractical. 
 
Vitamin D Glucuronides 
Discovery and identification 
Radiolabeled vitamin D pioneered the understanding of the vitamin D glucuronides in 
the late 1960s. The discovery emerged when Avioli et al. and Bell & Kodicek published 
findings of highly polar compounds in bile that were derived from intravenous 
administrations of the non-polar vitamin D in human and rat, respectively (100–102). Both 
research groups used β-glucuronidase digestion to deduce that a large portion of the polar 
compounds were glucuronide conjugates of vitamin D or its hydroxylated metabolites. 
Investigations on vitamin D glucuronides continued in the 1980s by several laboratory 
groups, confirming that the modification event occurs in both human and rat (8,103–106). 
The rates of biliary excretion were estimated numerous times, finding radiolabeled vitamin D  
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metabolites from 1% to 33% of the total bile and the glucuronide conjugate portion ranging 
from 6 to 55% of the excreted metabolites (Table 2.1). The evidence garnered posed the 
question as to the physiological significance of the vitamin D glucuronides. 
Structural determination of the conjugates in bile soon followed. Vitamin D has only 
one hydroxyl group on the 3’ carbon and conjugation at this position was demonstrated in 
rats given radiolabeled vitamin D by several routes of administration including intravenous, 
intraperitoneal, and oral (114) as well as in normal, untreated pigs’ bile (Horst et al., 
unpublished data). Location of the glucuronide on 25D has been more controversial. In 
chickens dosed intravenously with 25D, LeVan et al. observed only the 25’ position β-
glucuronide (108). Later experiments found conjugation at both 3’ and 25’ carbon positions 
from 25D-dosed rats and rat liver isolates (114–116). Isolation of the human UDP 
glucuronsyltransferase 1A4 (UGT1A4) enabled in vitro assessments of the conjugation by 
Wang et al. (117). It was found that UGT1A4 could attach the glucuronide at either the 3’ or 
25’ position, but only 25D-3β-glucuronide was detected in untreated human bile and plasma 
specimens. The position of the glucuronide on 25D remains uncertain; but, in humans, we 
can assume that under normal physiological conditions, only the 3’ position is conjugated 
while supraphysiological concentrations of 25D may induce conjugation at the 25’ position. 
Similar uncertainty is true for the glucuronide conjugated to 1,25D. In early work with 
1,25D-treated rats, Litwiller et al. proposed that conjugation occurred on the A-ring of 1,25D 
at either the 3’ or the 1’ position. More recent in vitro studies showed that human UGT1A4, 
when isolated, preferentially conjugated the glucuronide to the 25’ of 1,25D, while only a 
small amount of A-ring glucuronide was conjugated (118). Sufficient evidence is lacking for 
the structural determination of the 1,25D-β-glucuronide in normal physiological conditions.  
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While location of the glucuronide has not been deciphered, all structural work agrees 
that the reducing carbon on the glucuronide acid is in the β orientation. Mammalian 
organisms have a very limited ability to cleave β-linked sugars. Instead, the bacteria that 
resides in the lower GI expresses β-glucuronidases do, indeed, cleave the glucuronic acid 
from the D metabolite (119–121). Thus, the activity of glucuronidase has important relevance 
to understanding how the modification affects the vitamin once released into the intestine via 
bile. 
 
Enterohepatic circulation 
Enterohepatic circulation is a prominent mechanism in bile physiology. The 
fundamental idea is that the intestines absorbs bile-products into circulation; then, the liver 
re-secretes those products back into the intestines via bile and the cycle repeats itself. 
Because fecal samples contained less of a radiolabeled vitamin D injection than the amount 
appearing in bile, it was apparent that reabsorption was occurring (100,104,122). Estimations 
on the rate of vitamin D reabsorption were reported as 15% by Kumar et al., 25% by Gascon-
Barre, and 85% by Arnaud et al. (103,109,122). Kumar and colleagues also demonstrated 
how the liver re-secreted these metabolites by using intraduodenal administration of bile that 
had been collected from another intravenously-treated subject (8,103). Thus, the 
enterohepatic circulation pathway was deemed relevant for the vitamin D metabolites that 
had been identified in bile. 
The primary function of enterohepatic circulation is to conserve digestive 
constituents, yet vitamin D metabolites are not recognized to participate in digestive 
functions. A statement by David Fraser proposed that the function of glucuronidation on 
vitamin D metabolites is, instead, a protective mechanism to eliminate excess accumulation 
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and prevent toxicity particularly in times of excess sunlight (123). Fraser also criticized 
previous publications for using intravenous injections of vitamin D or metabolites in the free 
form, rather than bound to protein, such as DBP or albumin. His group then investigated this 
pathway to prove that biliary secretion of vitamin D glucuronides is only a function of waste 
removal. Furthermore, they estimated that the enterohepatic function could only provide 
trace amounts of unconjugated vitamin D metabolites (107). Shortly thereafter, Gascon-Barre 
wrote a review statement on the enterohepatic circulation of vitamin D explaining that, while 
functional, this system lacked physiological value. They then offered alternative schemes to 
justify its purpose, including recirculation to manage waste of vitamin D (124). With these 
negative revelations, the interest in enterohepatic circulation of vitamin D metabolites was 
abolished. 
The concern for the low biological activity of vitamin D glucuronides was a major 
factor contributing to the disinterest in enterohepatic circulation. Early studies by Kumar and 
colleagues used synthetic vitamin D-3β-glucuronide to assess the ability of these compounds 
in influencing dietary calcium absorption. After evaluating the doses required to increase 
serum calcium and to promote duodenal calcium transport by ex vivo rat guts, they concluded 
that the activity of the vitamin D-3β-glucuronide was 1/80 compared to the activity of  
vitamin D (125,126). Without apparent physiological relevance, studies on these compounds 
were abandoned. 
Studies on glucuronides in enterohepatic circulation were continued in other research 
areas and provided an alternative viewpoint. A recent review by Pellock and Redbindo 
explained how glucuronidation has a functional role in enterohepatic circulation for a broad 
range of molecules both endogenous and exogenous (119). It became evident that digestive 
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β-glucuronidase activity was insignificant and had no effect on the conjugated molecule 
during digestion until reaching the colon. In the colon, bacterial-derived β-glucuronidase 
cleaves the glucuronic acid, leaving the parent molecule unconjugated (119).  
Prior research on vitamin D enterohepatic circulation had focused entirely on the 
action at the duodenum, rather than the colon. To reignite investigations on the glucuronides, 
Goff and colleagues synthesized the 1,25D-25β-glucuronide and assessed its biological 
activity. As expected, the digestive contents from the colon of rats were effective at removing 
the glucuronide and releasing the 1,25D parent molecule (127). The group then successfully 
induced hormonal stimulation in the colon of mice and rats from both oral and subcutaneous 
administration of the 1,25D-glucuronide substrate (71,127). The duodenum, on the other 
hand, exhibited little or no response to either route of dosing. Interestingly, Koszewski et al. 
noted that the colon exclusively responded to the glucuronide of 1,25D, with little effect 
occurring from 1,25D treatments. These findings demonstrate how the biological activity of 
the vitamin D glucuronides is relevant only for the colon of most organisms. Ruminants are 
an exception as they also have bacterial β-glucuronidase present in the rumen and liberate the 
glucuronide prior to entry into the intestines. 
On the basis of the new revelations, a revision of the enterohepatic circulation of 25D 
has been proposed (128). In this model, Gao et al. explain that the 25D-glucuronide in bile 
travels to the colon where bacterial β-glucuronidase cleaves the glucuronide moiety. The 
proposed model then suggests that the free 25D within the colon could be activated locally 
by enteric 1α-hydroxylase to stimulate expression of calcium transport proteins without 
systemic renal activation (32). If true, this hypothesis would reinstate a physiological purpose 
for vitamin D glucuronides secreted in bile. 
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Conclusions 
Vitamin D research has been underway for a long time only to find that the hormone 
is far more complex than imagined. We have presented vast unknowns in just the aspect of 
vitamin D signaling in the intestines. From this background information, we pose the 
following uncertainties: First, what cells does the hormone target within the intestines? The 
location of VDR predicts a response in the crypts, but VDR-stimulated proteins only appear 
in the villi. Second, emerging information on 25D suggests that it could elicit hormonal 
effects, but only if taken up by the cells. However, within the lumen of the intestine, all 25D 
would be in free form, as DBP is not expected to remain folded in the digesta. Because the 
intestines express some 1α-hydroxylase, then perhaps free-25D within the lumen of the 
intestines, coming from diet or bile, could supply substrate for local 1,25D synthesis. Or 
maybe even act as a hormone itself through agonistic binding and stimulation of VDR. And 
third, would the glucuronide of 25D that has been confirmed in bile have the same effect, but 
only in the colon? These are all questions that are addressed in the following chapters of this 
dissertation through in vitro experiments in cultured cells and in vivo studies in the mouse 
model. 
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Tables 
Table 2.1  Appearance of vitamin D metabolites in bile.  
Publication 
Experimental 
Model 
Total Bile 
Collection 
Time (hrs) 
Total 
Metabolites 
in Bile* 
Estimated 
Glucuronides in 
Bile Metabolites* 
Total 
Glucuronides 
in Bile** 
Vitamin D, oral      
Clements et al., 1984 (107) Humans with 
cholecystectomy 
18 5% 24% 1.2% 
      
Vitamin D, intravenous      
Clements et al., 1984 (107) Humans with 
cholecystectomy 
18  5% 14% 0.7% 
Bell & Kodicek, 1969 (102) Rats, D-deficient 24  31% 40% 12% 
LeVan et al., 1981 (108) Chicks, D-
deficient 
24  33% 7% 2.3% 
Ayton & Martin, 1987 (106) Rats 24  6% 21% 1.2% 
Avioli et al., 1967 (100) Humans with 
cholecystectomy 
48  3-6% 31% 0.9-1.9% 
      
25D, intravenous      
Gascon-Barre, 1982 (109) Rats, D-deficent 3  5%   
Gascon-Barre, 1985 (105) Heterozygous 
Gunn Rats 
3  3-7% 6-15% 0.2-1% 
Larsson & Lorentzon, 1977 (110) Rats 8  1% 
 
 
Ayton & Martin, 1987 (106) Rats 24  10% 15% 1.5% 
     
 
1,25D, intravenous      
Wiesner et al., 1980 (8) Humans 6  16% 
 
 
Kumar et al., 1980 (103) Rats 24  25% 10% 2.5% 
Onisko et al, 1980 (111) Rats, D-deficient 24  65% 
 
 
Litwiller et al., 1982 (112) Rats 24  33% 
 
 
Ledger et al., 1985 (113) Humans with 
cholecystectomy 
24  19% 46-55% 8.7-10% 
Ayton & Martin, 1987 (106) Rats 24  13% 13% 1.7% 
*Values rounded to whole number digits.  
**Calculated by (Total Metabolites in Bile) x (Estimated Glucuronides in Bile Metabolites). 
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Figures 
 
Figure 2.1  Summary of intestinal 1,25D-mediated calcium absorption. Dietary calcium 
enters the apical membrane of the cell via TRPV6 and possibly by TRPV5 and Cav1.3. 
Cytosolic calcium is transferred across the cell via calbindin D[9K]. The calcium is extruded 
across the basolateral membrane via PMCA1b and NCX1. Paracellular absorption occurs via 
TJ (tight junctions) containing claudins 2, 12, and 15. Image adapted from Diaz de Barboza 
et al. under terms of the Creative Commons Attribution-Noncommercial License (37). 
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Abstract 
1,25-Dihydroxyvitamin D3 (1,25D) elicits a transcriptional response in the intestines. 
Assessments of this response are often derived from crude tissue homogenates and eliminate 
the ability to discriminate among different cell types. Here, we used an RNA in situ 
hybridization assay, RNAScope (Advanced Cell Diagnostics, Newark, CA), to identify the 
cells in the intestine that respond to 1,25D with expression of cytochrome P450 family 24 
subfamily A member 1 (Cyp24) mRNA. Mice were gavaged with a single bolus dose of 
1,25D to target the duodenum or a glucuronic acid conjugate of 1,25D, 1,25D-Gluc, to target 
the colon. Q-PCR analysis of Cyp24 mRNA verified that the 1,25D-induced responses were 
present. RNAScope revealed that the mRNA response present after six hours is limited to 
mature enterocytes exposed to the intestinal lumen in both the duodenum and colon. No 
detectable expression was observed in goblet cells, lamina propria, muscularis mucosa 
muscle, submucosa and submucosal lymphoid follicles, or tunica muscularis. Our findings 
have identified epithelial enterocytes to be the intestinal targets for 1,25D in both the 
duodenum and colon. 
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Introduction 
1,25-Dihydroxyvitamin D3 (1,25D) is the active form of vitamin D3 that binds to the 
vitamin D receptor (VDR) and initiates events that modulate gene expression. These events 
lead to transcriptional upregulation of calcium transport proteins as well as proteins involved 
in apoptosis, cell differentiation, and inflammation [1, 2]. In the intestines, 1,25D increases 
the uptake of dietary calcium, but the localization of the mRNA response within the tissue 
architecture has not been confirmed. 
In the mouse, both the duodenum and colon respond to orally administered 1,25D [1]. 
The colon, however, requires larger doses to surpass the small intestine. These larger doses 
of 1,25D inadvertently perturb systemic 1,25D and may cause deleterious effects. To 
eliminate potential complications, our laboratory previously synthesized a therapeutic 
glucuronide of 1,25D, β-glucuronic-1,25D (1,25D-Gluc) [3]. Conjugation with a glucuronic 
acid moiety via beta-linkage renders the 1,25D-Gluc molecule inaccessible to mammalian 
digestive enzymes. When ingested, the glucuronide moiety remains intact through the small 
intestine until arriving in the colon. There bacterial glucuronidases in the colon hydrolyze the 
beta-linked acid and liberate 1,25D. Thus, 1,25D-Gluc pharmacologically delivers 1,25D to 
the colon for hormonal action [3, 4].  
Activation of VDR by 1,25D-binding induces expression of an array of genes 
containing vitamin D response elements (VDREs) [5]. One particular gene, cytochrome P450 
family 24 subfamily A member 1 (Cyp24), encodes for the 24-hydroxlase that initiates 
degradation of 1,25D in a negative feedback manner [6]. The promoter region of this gene 
contains two VDREs and, consequently, is robust and sensitive to the actions of ligand-
bound VDR [7]. Thus, increased abundance of Cyp24 mRNA, as assessed by quantitative  
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real time PCR (Q-PCR), is utilized as an index of tissue responsiveness to 1,25D. 
Unfortunately, this method involves RNA extraction from crude tissue homogenization and 
does not allow for determination of the individual cells responding to 1,25D within the tissue. 
Previous immunohistochemical analyses of VDR and 1,25D-induced proteins 
indicate that the strongest response in the intestines occurs in the epithelial layer, but 
confirmation of expression at the transcriptional level has not yet been demonstrated [8, 9, 
10, 11]. Recent advances in RNA in situ hybridization (ISH) have enabled chromogenic 
detection of individual mRNA targets in tissue sections. In the RNAScope assay by 
Advanced Cell Diagnostics (Newark, CA), hybridizations between modified DNA probes 
and the complementing target mRNA undergo an amplification that enhances sensitivity with 
minimal background detection [12]. In the following study, we use RNAScope to assess the 
induction of Cyp24 mRNA by 1,25D in both the duodenum and colon of mice to confirm the 
hypothesis that the 1,25D-response occurs in the epithelial cells of the intestine. 
 
Methods 
Animals  
Twenty-one adult male CD1 mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). Mice were housed in groups and fed a standard diet (Teklad 2014, Madison, 
WI) ad libitum, with unlimited access to food and water in a 12-hour light/dark cycle. Rodent 
care and handling procedures were approved by the Iowa State University Institutional 
Animal Care and Use Committee. 
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Animal experiments  
1,25-Dihydroxyvitamin D3 was purchased from Sigma Aldrich (St. Louis, MO), and 
1,25D-Gluc was synthesized by methods previously described [3]. Compounds were 
dissolved in 100% ethanol and stored at -86o C. Concentrations of 1,25D and 1,25D-Gluc 
were quantified by using the molar extinction coefficient of 18,300 M-1cm-1 at 264 nm 
absorbance. Oral treatments of ethanol, 1,25D, or 1,25D-Gluc were diluted with peanut oil to 
a volume of 50 μL and gavaged in a single dose. Three mice were gavaged with ethanol in 
peanut oil to serve as 0 pmol controls. Treatment groups included nine mice each and were 
further divided into three doses: 6 pmol, 12 pmol, or 24 pmol (n=3 mice per dose per 
treatment). Six hours after treatment, mice were anesthetized by inhalation of isoflurane and 
euthanized by guillotine. Blood was collected from the cervical stump into heparinized tubes. 
Blood plasma samples were stored at -20o C and used for 1,25D analysis by 
radioimmunoassay performed by Heartland Assays (Ames, IA). Two 1-cm segments were 
collected from the duodenum and proximal colon of mice. Intestinal segments were flushed 
with ice-cold 0.9% sodium chloride solution. One segment from each tissue was 
homogenized in 1 mL TRIzol Reagent (Invitrogen, Carlsbad, CA) and stored at -86o C until 
RNA extraction. The other segment was fixed with 10% formalin in neutral phosphate buffer 
for 24 hours, then immediately embedded in paraffin for RNA ISH. 
 
RNA extraction 
Total RNA was extracted from TRIzol homogenates. RNA was solubilized by using 
the recommended chloroform separation per TRIzol reagent protocol (Invitrogen, Carlsbad, 
CA). The upper aqueous phase was removed and subjected to RNeasy mini prep column 
(Qiagen, Germantown, MD). Total RNA extraction was performed as recommended with an 
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added wash (2 M NaCl and 2 mM EDTA at pH 4.0) as previously described [4]. Columns 
were eluted with 50 μL nuclease-free water and the total RNA concentration determined by 
using the absorbance at 260 nm wavelength. RNA quality was verified with 260:280 nm of 
approximately 2.0. Samples were diluted to 0.5 μg total RNA/uL of nuclease-free water. 
cDNA was synthesized from 1 μg of RNA by using random hexamer primers and 
SuperScript III First Strand Synthesis (Invitrogen, Carlsbad, CA). cDNA samples were 
diluted to a final volume of 100 μL with Tris-EDTA buffer (10 mM Tris and 1 mM EDTA) 
and stored at -20o C for analysis by QRT-PCR. 
 
Q-PCR analysis  
Q-PCR was performed on an Mx3005p thermal cycler by Stratagene (La Jolla, CA). 
cDNA was amplified with PerfeCTa SYBR Green FastMix Low Rox (Quanta Biosciences, 
Inc, Gaithersburg, MD) for 45 cycles of melting (96o C, 3 s) and annealing (54o C, 30 s). 
Primers were synthesized by Integrated DNA Technologies (Coralville, IA) and include 
murine Cyp24 [5’ CACACGCTGGCCTGGGACAC (forward) and 5’ 
GGAGCTCCGTGACAGCAGCG (reverse)], and murine Gapdh [5’ 
GAAGGTCGGTGTGAACGGATTTGGC (forward) and 5’ 
TTGATGTTAGTGGGGTCTCGCTCCTG (reverse)]. Q-PCR data are expressed as CT of 
Cyp24 relative to the CT of Gapdh (dCT) and normalized to the average dCT of control 
animals (ddCT). 
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RNAScope in situ hybridization 
Paraffin-embedded tissues were cut to 5 μm sections by using a rotary microtome. 
Immediately following sectioning, RNA ISH was completed per RNAScope 2.0 HD Red 
Manual Detection Kit protocol with pretreatment optimization (Advanced Cell Diagnostics, 
Newark, CA). Positive (Mus peptidylprolyl isomerase B) and negative (E. coli 
dihydrodipicolinate reductase) oligo probes were used as procedural controls. Oligo probes 
for murine Cyp24 were custom designed and are proprietary to Advanced Cell Diagnostics. 
Hybridization of probes to the mRNA and amplification of the hybridizations were 
performed per protocol and detected by using Fast Red chromogenic dye with hematoxylin 
counterstain of the tissue. mRNA signal particles were counted by using ImageJ software 
(US NIH, Besthesda, MD) with a Colour Deconvolution plug-in. Particle signal was counted 
if the particle size was within 4 to 50 pixels in diameter and at least 0.8 circularity. Particle 
count was determined as the average of five fields from each section observed at 40x 
magnification.  
 
Statistical analysis 
Data were analyzed by using the GLM procedure for ANOVA comparisons with 
Tukey-Kramer adjustments for multiple comparisons and the REG procedure for correlations 
in SAS statistical software (SAS Institute Inc, Cary, NC). 
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Results 
Appearance of 1,25D into blood plasma 
Plasma 1,25D concentrations were assessed for control mice and mice that received 
24 pmol of 1,25D or 1,25D-Gluc (Figure 3.1). Six hours after treatment, plasma [1,25D] 
were significantly greater for the 1,25D-treated animals (559 ± 82 pmol/L) than for control 
animals (160 ± 17 pmol/L, P < 0.01). An equimolar dose of 1,25D-Gluc also yielded 
significantly greater concentrations of plasma 1,25D (416 ± 52 pmol/L) than for control 
animals (P < 0.05). Although numerically different, there was no statistical difference 
between 1,25D and 1,25D-Gluc treatments (P = 0.4). The observation of equimolar 1,25D 
and 1,25D-Gluc doses causing similar increases in plasma [1,25D] verifies successful 
hydrolysis of the glucuronic acid moiety in 1,25D-Gluc and the subsequent internalization of 
liberated 1,25D. 
 
Q-PCR from crude tissue homogenates 
Q-PCR analysis of Cyp24 mRNA was used to quantify the intestinal response to 
1,25D. In the duodenum, all doses of 1,25D (6 pmol, 12 pmol, and 24 pmol) had significantly 
greater abundances of Cyp24 mRNA than controls (P< 0.02; Figure 3.2A). The responses 
followed a dose-dependent relationship in that the effect of the lowest dose (6 pmol, 4.5 ± 0.5 
ddCT) was statistically different from the effect of the highest dose (24 pmol, 8.0 ± 0.3 
ddCT), and no differences were observed between adjacent increments. In the colon, only the 
24 pmol 1,25D dose was enough to elicit a small, but statistically significant increase in 
Cyp24 expression compared with the control colons (3.3 ± 0.9 ddCT, P< 0.05; Figure 3.2B).  
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Use of 1,25D-Gluc enabled targeting of 1,25D to the colon of mice. Mice were 
treated with 1,25D-Gluc in equimolar increments to 1,25D dosages. No increase in Cyp24 
mRNA expression was observed in the duodenum, despite a 2.6-fold increase in plasma 
[1,25D] (Figure 3.2C). In the colons, the effects of all 1,25D-Gluc doses were statistically 
greater than those of controls (P< 0.05), but not different from one another (Figure 3.2D), 
suggesting a maximal threshold was met with 6 pmol 1,25D-Gluc. The lack of duodenal 
stimulation by 1,25D-Gluc indicates that the glucuronide-bound complex delivers no 
hormonal stimulation and further supports the assumption that 1,25D-Gluc is biologically 
inactive until glucuronide hydrolysis by bacterial enzymes [3,4]. 
 
RNAScope in situ hybridization of 1,25D-stimulated intestines 
RNAScope hybridizations were performed with mus Cyp24 probes to locate 1,25D-
dependent responses in duodenal and colon tissues. This assay amplifies the mRNA:probe 
hybridizations in tissue sections for visualization under light microscopy. Cyp24 mRNA was 
observed in all 1,25D-treated duodena and 1,25D-Gluc -treated colons, whereas the duodena 
and colons from control animals had no visible expression (Figure 3.3). Increases in the dose 
of 1,25D or 1,25D-Gluc increased the density of hybridizations until reaching saturation such 
that individual mRNA signals could not be distinguished. In both the duodenum and colon, 
Cyp24 mRNA transcripts were present only in epithelial enterocytes. Additionally, Cyp24 
mRNA was more concentrated in mature enterocytes nearest the interior of the intestinal 
lumen rather than in enterocytes deep in the crypt regions. Goblet cells, lamina propria cells, 
submucosa cells, submucosal lymph follicles, and smooth muscle tissue were devoid of 
Cyp24 mRNA transcripts.  
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Quantitative analysis of the RNAScope hybridization was performed in ImageJ 
software. The images were filtered by using the Colour Deconvolution plug-in to isolate the 
Fast Red chromogenic color. Once filtered, a particle count was performed as described in 
section 2.5. The 24 pmol dose of 1,25D yielded an average particle count for the duodenum 
that was significantly greater than for the control duodenum, but not statistically different 
among other doses of 1,25D. No statistical differences were observed in the colons across all 
doses of 1,25D-Gluc, despite significant increases observed by Q-PCR (Figure 3.4B). An 
inability to distinguish individual mRNA signals at high abundance may have interfered with 
particle count determination and caused a high degree of variation in the measurement. 
Variation in particle count may also be affected by the random selection of fields obtained, 
the sensitivity of the optics and analysis software, and/or the orientation of the tissue when 
paraffin-embedded. We then compared the RNAScope Cyp24 particle count with the 
corresponding Q-PCR Cyp24 mRNA ddCT for each animal (Figure 3.4C, D). By using 
Pearson’s R (ρ) statistical method, we observed significant positive correlations between Q-
PCR and particle count for both tissues (P < 0.05). 
 
Discussion 
As a steroid hormone, 1,25D targets cells in the intestine to increase the mRNA 
expression of proteins vital for adequate calcium absorption. Through the use of RNAScope 
ISH, we observed that the 1,25D-mediated mRNA response is distinctly limited to 
enterocytes in both the duodenum and colon of mice 6 hours after treatment (Figure 3.3). 
Furthermore, the mRNA expression is most abundant in enterocytes of the duodenal villi and 
colonic tips rather than in crypt regions. These findings are consistent with published 
literature on the 1,25D-mediated response that used immunohistochemistry. Multiple 
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assessments of intestinal VDR protein had predicted that the response would occur in the 
enterocyte layer [8, 9, 10, 11]. Wang et al. and Sidler-Lauff et al. additionally noted an 
absence of VDR in accessory cells such as secretory, muscle and lymphatic cells, 
corresponding with our mRNA data [10, 11]. Interestingly, Colston et al. and Sidler-Lauff et 
al. observed the greatest density of VDR in crypt enterocytes rather than in the villi or tips of 
the intestinal architecture as we have shown. Both researchers also demonstrated the 
appearance of vitamin D-stimulated proteins alkaline phosphatase and calbindin D9K, 
respectively, throughout the epithelial layer. These stimulated proteins were most abundant 
in the villi rather than in crypts, precisely corresponding with our findings [10, 13]. Taken 
together, the presence of VDR, the transcription of 1,25D-stimulated mRNA, and the 
translation of 1,25D-stimulated proteins all agree that the 1,25D-mediated response occurs in 
intestinal epithelial cells at villous or tip regions. 
Our validation assessments revealed contradictions between circulating 1,25D and the 
intestinal responses. We found that even when 1,25D-Gluc caused a 2.6-fold increase in 
plasma [1,25D], the expected response in the duodenum was absent. Similarly, when plasma 
[1,25D] increased 3.5-fold from 1,25D-treatment, the response in the colon was blunted and 
could have instead resulted from digestive passage of 1,25D. This is a curious finding as 
current theories propose that 1,25D, released from the kidney, circulates in the blood to reach 
the duodenal cells by presumably crossing the basolateral membrane of enterocytes [1, 13]. 
Our data suggest that the duodenum, and possibly the colon, may not respond directly to 
fluctuations in circulating 1,25D. A similar phenomenon had been demonstrated in the mouse 
by Koszewski et al. [4]. They found that the colon responded to subcutaneous administration 
of both 1,25D and 1,25D-Gluc treatments, but these responses were abolished when the 
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intestine of the mouse was surgically tied off below the bile duct to prevent passage of bile 
and digesta. The data collected by Koszewski et al. suggested that the colon receives 
circulating 1,25D and/or 1,25D-Gluc via bile delivery to the apical membrane rather than via 
circulation to the basolateral membrane. Our finding that the location of the response is only 
in the epithelial cells further supports the notion of bile delivery of 1,25D into the intestine. 
While endogenous 1,25D and 1,25D-Gluc have not yet been observed in bile, a glucuronide 
of 25-hydroxyvitamin D, the precursor to 1,25D, has been shown in human plasma and bile 
[14,15]. Future research will be needed to clarify the role for bile and vitamin D glucuronides 
in the 1,25D-mediated activity of the intestinal epithelium. 
In conclusion, we have confirmed that the intestinal 1,25D-mediated response occurs 
in enterocytes at the villi of the duodenum and the tips of the colon by in situ observation of 
1,25D-stimulated mRNA. These data correspond with previous work using protein 
immunohistochemistry. Lastly, we noted a lack of stimulation in the duodenum despite 
increased plasma [1,25D] and considered the possibility that the location of the response may 
indicate a physiological mechanism of enterohepatic signaling for 1,25D. 
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Figures 
 
 
Figure 3.1  Oral treatments of 1,25D and 1,25D-Gluc increase plasma [1,25D]. Bars 
depict mean ± standard error of the mean. *Statistically different from control (P<0.05).  
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Figure 3.2  The mRNA response to 1,25D occurs primarily in the duodenum, whereas 
the response to 1,25D-Gluc occurs in the colon. Cyp24 ddCT data are calculated as CT 
normalized to Gapdh and relative to the average of controls. Bars depict mean ± standard 
error of the mean. *Statistically different from control with 0 pmol dose (P <0.05). 
**Statistically different between groups (P <0.05).  
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Figure 3.3  The 1,25D-mediated Cyp24a1 mRNA response appears in epithelial 
enterocytes in both the duodenum and colon. Representative images obtained from 
RNAScope hybridization with Cyp24a1 probes (indicated by black arrows) at 20x 
magnification.  
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Figure 3.4  Particle count analysis of RNA in situ hybridization and its correlation to 
QRT-PCR data. Horizonal lines depict means and whiskers represent minimum and 
maximum (A, B). Error intervals depict 95% confidence (C, D). *Statistically different from 
0 pmol controls (P<0.05). Statistical significance of xy correlations (P) determined by 
Pearson’s R analysis (ρ).  
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Abstract 
25-Hydroxyvitamin D3 (25D) is the predominant circulating metabolite of vitamin D 
and serves as the precursor for 1α,25-dihydroxyvitamin D3 (1,25D), the hormonal form of 
vitamin D. The presence of 1α-hydroxylase in the intestine suggests that 1,25D can be 
produced locally from 25D, but the effects of oral 25D on the intestine have not been 
determined. We investigated the acute intestinal response to orally administered 25D in 
comparison to 1,25D in mice by assessing mRNA induction of Cyp24, a vitamin D-
dependent gene. The mechanism of action then was determined through in vitro analyses.  
Mice were administered orally with either 25D or 1,25D and euthanized 4 hrs later to 
evaluate expression of Cyp24 in the duodenum. Tissues were analyzed quantitatively by Q-
PCR and qualitatively by RNA in situ hybridization. An in vitro model was developed to 
reflect the intestinal lumen with both HT-29 and Caco2 human intestinal cell lines. By using 
our in vitro model, we manipulated the 1α-hydroxylase with ketoconazole-mediated 
inhibition and CRISPR-mediated gene editing, and then measured the CYP24 mRNA 
responses to 25D and 1,25D treatments. We found that oral 25D caused a significant increase 
in expression of Cyp24 mRNA in the duodenum of mice with as little as 200 pmol of 25D. 
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The induced Cyp24 mRNA was localized to the epithelial cells of the intestines. In vitro, the 
intestinal model enabled a response to 100 nM 25D treatment, yet inhibition of 1α-
hydroxylase and knock-down of CYP27B1 did not diminish the response. In mice, oral 25D 
elicits a response in the duodenum similar to, but with less sensitivity than that of 1,25D. In 
vitro assessments suggest that the response from 25D does not require activation by 1α-
hydroxylase and that 25D within the intestinal lumen acts as a vitamin D receptor agonist. 
 
Introduction 
25-Hydroxyvitamin D3 is a metabolic product of vitamin D and the precursor to the 
calcium-regulating hormone, 1α,25-dihydroxyvitamin D3 (1,25D). As a hormone, 1,25D 
regulates expression of genes, particularly of those related to calcium absorption and 
transport. Conversion of 25D to 1,25D occurs in the kidneys by 1α-hydroxylase (1α-OHase); 
however, expression of 1α-OHase has been observed in the intestines (1,2). The presence of 
1α-OHase in the intestines would imply that 25D consumed from the diet or secreted into the 
intetines could be activated to 1,25D and then could affect intestinal cell function prior to 
transmembrane absorption into the body. Evidence of 1,25D accumulation in the human 
colon has been measured previously, suggesting that local hydroxylation does occur (3). We 
hypothesized that orally consumed 25D would elicit a vitamin D hormonal response in the 
intestine via enteric 1α-hydroxylation and subsequent activation of the vitamin D receptor 
(VDR). Evaluation of the duodenal response to 25D was performed in mice, and then the 
mechanism of action was investigated through in vitro inhibition and knock-down analyses. 
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Methods 
Experimental reagents  
Vitamin D, 25D, and 1,25D (>98% pure, Sigma Aldrich) were dissolved in 100% 
ethanol and stored at -80oC. Chemical purity was verified by HPLC, and concentrations were 
determined by measuring the UV absorption at 265 nm and using the molar extinction 
coefficient of 18,300 mol-1L-1. Ketoconazole (Tocris Bioscience), a cytochrome p450 
inhibitor, was dissolved in dimethyl sulfoxide (DMSO) and stored at 4oC for use with in vitro 
inhibition assays. 
 
Animal experiment 
Thirty-one adult male C57BL6 mice (Jackson Laboratories) were housed in groups of 
3 or 4 mice and fed a standard rodent chow diet (Teklad 2014) ad libitum in a 12-hour 
light/dark cycle. Care and handling of mice were approved by the Iowa State University 
Institutional Animal Care and Use Committee. Mice weighing between 20 and 22 g were 
divided randomly into treatment groups to receive ethanol, 25D, or 1,25D. Ethanol was used 
as a placebo treatment for control mice (n=3). Sixteen mice were given 25D in doses of 100, , 
200, 500, or 1000 pmol (n=4 per dose). The remaining 12 mice received 1,25D in doses of 5, 
12.5, or 25 pmol (n=4 per dose). Each mouse was given the designated treatment in a single 
oral dose carried in 50 μL of peanut oil. Four hours after the oral treatments, the mice were 
euthanized and two 1-cm intestinal segments from the duodenum that were approximately 
one cm distal to the pylorus were collected. The first segment was homogenized in TRIzol 
(Invitrogen) for RNA extraction, and the second was fixed for 24 hrs in 10% neutral formalin 
solution and embedded in paraffin for RNA in situ hybridization (RISH). 
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Cell culture experiments 
Human colon adenocarcinoma HT-29 and Caco2 cell lines (American Type Culture 
Collection) were cultured under standard conditions (5% CO2 in room air, 37
oC) in 
Dulbecco’s Modified Eagle Medium (Gibco) and Eagles Minimum Essential Medium 
(Corning Cellgro), respectively, and supplemented with 10% fetal bovine serum (FBS) and 
0.2% penicillin-streptomycin. Caco2 cells were maintained up to passage 16 and HT-29 cells 
up to passage 20. All in vitro experiments were conducted in 6-well plates seeded with 2x106 
cells per well of HT-29 or Caco2 cells, and growth media was replaced 24 hours later with 3 
mL media containing the vitamin D treatments. Experiments were repeated independently 
three times (n=3) with one control in each experiment. At the end of the indicated time, 
treatment media were removed, and then cells were lysed in 500 μL TRIzol for RNA 
extraction. 
 
Cell transformation 
HT-29 cells were transformed by clustered regularly interspaced short palindromic 
repeats (CRISPR) endonuclease-mediated mutation with Cas9 2NLS nuclease (Synthego) 
and a synthetic guide RNA (sgRNA; Synthego) for human cytochrome p450 family 27 
subfamily B member 1 (CYP27B1) [5’-GUGGUACUCUCGGUAGCCUA-3’]. 
Transformations were performed by using Lipofectamine 3000 (Invitrogen) with Cas9 2NLS 
nuclease and sgRNA in Opti-Mem medium (Gibco). Mutagenesis was verified by western 
blot analysis of the expressed CYP27B1 protein, 1α-OHase. 
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RNA quantification 
Total RNA was extracted from tissue homogenates and cell lysates for cDNA 
synthesis followed by Q-PCR analysis to determine relative expression of Cyp24. RNA was 
separated by chloroform with TRIzol reagent. The upper phase was removed and subjected to 
RNeasy Mini Prep RNA isolation column (Qiagen). Total RNA isolation was performed as 
recommended with an added column wash containing 2 M NaCl and 2 mM EDTA at pH 4.0. 
Columns were eluted with 50 μL nuclease-free water for tissue homogenates and 30 μL 
nuclease-free water for cell lysates. The total RNA concentration was determined by UV 
spectroscopy at A260 and quality was assessed by ratio of A260/A280. cDNA was 
synthesized from 1 μg of RNA by using random hexamer primers and SuperScript III First 
Strand Synthesis (Invitrogen). cDNA samples were diluted 1:5 for tissue homogenates and 
1:3 for cell lysates with Tris-EDTA buffer (10 mM Tris and 1 mM EDTA) and stored at -20o 
C. Tissue homogenates were again diluted 1:6 with Millipore water for Q-PCR. Tissue and 
cell cDNA samples were amplified with Cyp24 or Gapdh primers (Table 4.1) and PerfeCTa 
Syber Green FastMix (Quanta Biosciences) on a CFX96 C1000 Real Time Thermo Cycler 
(Bio-Rad) for 45 cycles of melting (96o C, 3 s) and annealing (54o C, 30 s). Use of Gapdh as 
a housekeeping gene was verified to have no differences by statistical analysis of Q-PCR 
values. Resulting data are expressed as threshold cycles (CT) of Cyp24 normalized to Gapdh 
(dCT) and relative to the average of control animals or to the control well of the respective in 
vitro experiment (ddCT). 
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RNA in situ hybridization 
RISH was performed to qualitatively assess expression of Cyp24 in the mouse 
duodenum. Formalin-fixed and paraffin-embedded tissues were sectioned (5 μm) and then 
hybridized with Cyp24 oligo probes by using the RNAScope 2.0 HD Red Manual Detection 
Kit (Advanced Cell Diagnostics). Oligo probes for RNAScope are proprietary to Advanced 
Cell Diagnostics. Positive (Mus peptidylprolyl isomerase B, expressed in all mouse cells) and 
negative (E. coli dihydrodipicolinate reductase, not found in mammalian cells) probes were 
used as procedural controls. Following hybridization, sections were counterstained with 
hematoxylin and 0.02% ammonia for bluing. Tissues were examined qualitatively by light 
microscopy at 40x magnification. 
 
Protein and western blot analysis 
Effectiveness of the endonuclease-mediated mutagenesis of CYP27B1 in HT-29 and 
Caco2 cell lines was determined by western blotting. Trypsinized cells were pelleted, washed 
in 0.01 M phosphate-buffered saline (PBS), resuspended in RIPA buffer with protease 
inhibitor, and then stored at -20oC. Total protein was quantified by using the Quick Start 
Bradford protein assay (Bio-Rad). Sample proteins were separated by electrophoresis on a 
10% Tris-glycine polyacrylamide gel (Norvex), and then transferred to a polyvinylidene 
difluoride membrane. The membrane was blocked in buffer solution of PBS with 0.1% 
Tween-20 (PBST) and 5% w/v non-fat dried milk. The blocked membrane then was 
incubated overnight (4oC) with primary antibody (detailed below) in PBST buffer with 5% 
w/v non-fat dried milk and 0.02% sodium azide, followed by incubation with horseradish 
peroxidase-conjugated secondary antibody in PBST with 1% w/v non-fat dried milk for 2 hrs 
at room temperature. Antibodies used include mouse anti-CYP27B1 primary antibody (1α-
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OHase, mol wt. 56 kD) at 1:500 (Santa Cruz Biotechnologies) with goat anti-mouse 
secondary antibody in a dilution of 1:10,000 (Santa Cruz Biotechnologies) and rabbit anti-
GAPDH primary antibody (glyceraldehyde-3-phosphate dehydrogenase; mol wt. 37 kD) at 
1:2,000 (Abcam) with goat anti-rabbit secondary at 1:20,000 (Invitrogen). Blots were 
developed by using enhanced chemiluminescence (Pierce) and imaged in a ChemiDoc 
imaging system (Bio-Rad). 
 
Dose-response mathematical modeling 
 Dose-response analyses were modeled after the Michaelis-Menten kinetics equation 
where reaction rate (ν) is represented by relative responses from Q-PCR (ddCT), maximal 
velocity (Vmax) is represented by maximal effect (Emax), the Michaelis constant (KM) is 
represented by the effective concentration at 50% (E50), and the substrate concentration 
remains notated as [S].  
Michaelis-Menten Kinetics Equation 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 + [𝑆]
 
Modified Michaelis-Menten Dose-Response Equation 
𝑑𝑑𝐶𝑇 =
𝐸𝑚𝑎𝑥[𝑆]
𝐸𝐶50 + [𝑆]
 
Statistical analyses 
Statistical analyses were performed on GraphPad Prism 5 (GraphPad Software) and 
SAS version 9.4 (SAS Institute Inc). Bar graph data depict analyses by ANOVA comparisons 
with Tukey-Kramer adjustments for multiple comparisons. Values are expressed as mean +/-  
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SEM. P values are considered significant when <0.05. Concentration curves were fitted to 
modified Michaelis-Menten dose-response equation, and comparisons were made between 
best-fit lines. 
 
Results 
25-Hydroxyvitamin D elicits a transcriptional response in the duodenum of mice 
 Mice were given a single oral dose of 25D to evaluate hormonal responses in the 
duodenum. Four hours after ingestion, duodenal Cyp24 mRNA expression was upregulated 
in a dose-dependent manner (100 pmol 25D by 1.0 ± 0.5 ddCT; 200 pmol 25D by 3.3 ± 0.8 
ddCT; 500 pmol 25D by 5.7 ± 0.8 ddCT; 1000 pmol 25D by 6.4 ± 0.3 ddCT; Figure 4.1A). 
These responses became statistically different from controls (0 ± 0.15 ddCT) with 200 pmol 
25D (P=0.002). We also observed a small response with the lowest dose of 100 pmol 25D; 
however, our statistical power was not great enough to discern significance from that dosage. 
All doses of 1,25D induced Cyp24 mRNA expression compared to controls (5 pmol 1,25D 
by 9.0 ± 0.2 ddCT, P<0.0001; 12.5 pmol 1,25D by 9.5 ± 0.1 ddCT, P<0.0001; 25 pmol 
1,25D by 10.0 ± 0.2 ddCT, P<0.0001). Qualitatively with RISH, we observed that Cyp24 
mRNA induced by both 1,25D and 25D and appeared only in the epithelial cells lining the 
duodenal villi (Figure 4.1B); a response pattern that was identical to previously published 
RISH data by our group (4). 
 
Effect of 25-hydroxyvitamin D in vitro 
The induction of Cyp24 observed in mice insinuated that intestinal cells grown in 
culture would also respond to 25D. Under cell culture conditions supplemented with 10% 
FBS, both HT-29 and Caco2 human colon adenocarcinoma cell lines exhibited the ability to 
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upregulate CYP24 from 100 nM of 1,25D (HT-29, 11.1 ± 0.1 ddCT; Caco2, 13.7 ± 0.6 
ddCT), but not from equimolar amounts of 25D or vitamin D (Figure 4.2). We concluded 
that these cell conditions were not adequate for evaluating the mechanism of the response 
that we had observed in mice.  
 
Removal of FBS from treatment media enables response to 25-hydroxyvitamin D 
We considered that the FBS used in cell culture contains proteins that bind to 25D 
such as vitamin D binding protein (DBP) and albumin. Our RISH data suggests that only 
epithelial cells are involved in the response and that these cells interact with the intestinal 
lumen. Because orally consumed proteins within the intestinal lumen are denatured by 
digestion, one can assume that 25D in digesta would be free and not bound to protein. Thus, 
use of FBS in media may not reflect the environment of the intestinal lumen. After 
evaluation, we found that using less FBS (1% or 0.1%) in culture media enabled a response 
by HT29 and Caco2 to physiological concentrations of 100 nM 25D (Figure 4.2). No effect 
of FBS-enrichment was found for the response by 1,25D. Equimolar concentrations of 
vitamin D did not induce a response in any of the conditions tested. These data suggest that 
sequestration by serum proteins greatly impairs the response from 25D in cultured intestinal 
cells.  
 
Inhibition of the 1α-hydroxylase using ketoconazole has no effect on the 25-
hydroxyvitamin D-mediated response 
Ketoconazole inhibits cytochrome P450 enzymes, including the 1α-OHase necessary 
for 1,25D synthesis. HT-29 and Caco-2 cells were treated with 100 nM 25D or 1,25D and co-
treated with either 10 μM ketoconazole in DMSO or DMSO alone (Figure 4.3). In both cell 
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lines, ketoconazole had no effect on the CYP24 expression induced by 1,25D. Caco2 cells 
co-treated with ketoconazole responded to 25D (9.3 ± 0.2 ddCT) as well as with DMSO co-
treated cells (8.9 ± 0.4 ddCT, P = 0.4). HT-29 cells co-treated with ketoconazole exhibited a 
greater response to 25D (10.7 ± 0.2 ddCT) compared to DMSO controls (7.1 ± 0.4 ddCT, P = 
0.001). These data demonstrate no effect from inhibition of 1α-OHase and suggest that the 
protein may not be involved in the response from 25D. 
 
Knock-down of 1α-hydroxylase and dose-response analysis reveals agonist activation.  
Our hypothesis suggests that the 1α-OHase is required for 25D to induce CYP24 
expression in intestinal cells, but inhibition of the 1α-OHase had no effect on the responses. 
To ensure that the lack of effect by ketoconazole was not a result of failure to inhibit the 1α-
OHase, a knock-down of HT-29 cells was performed by using endonuclease-mediated 
CRISPR excision of CYP27B1 to create HT-29 CYP27B1em1Jgoff cells. The lower expression 
of the 1α-OHase in HT-29 CYP27B1em1Jgoff was verified by western blot analysis (Figure 
4.4A). Expression of the 1α-OHase was not detectable in Caco2 cells; therefore, a knock-
down of these cells was not created. We then performed a dose response analyses for HT-29 
CYP27B1+, HT-29 CYP27B1em1Jgoff, and Caco2 cells by measuring the CYP24 response to 
various doses of 25D and 1,25D (Figure 4.4B-D). In compiling our data, we did not use the 
relative 100% scale for response effect as is traditionally done for dose-response curves. 
Instead, we used a modified Michaelis-Menten analysis (described in Methods) that enables 
assessment of the response as a measure of VDR activation and allows interpretation of the 
Emax and EC50 as kinetic dimensions similar to Vmax and KM, respectively. The calculated 
Emax and EC50 values are shown in Table 4.2. Emax values describe the VDR ligand-activated 
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transcriptional response. We found that Emax differed slightly between HT-29 and Caco2 
cells, but such differences in transcriptional rates are expected between cell lines. The Emax 
values between 1,25D and 25D ligands were consistent for both HT29 CYP27B1+ and Caco2 
cells and confirm that the activity downstream of VDR activation is identical between 
ligands. Analysis of the EC50 data describes differences in ligand-receptor affinity and 
reveals characteristics of the reaction process. We found that knock-down of 1α-OHase did 
not affect the EC50 for 1,25D (P = 0.15) or for 25D (P = 0.33). Interestingly, the 25D-
mediated response to Caco2 cells was more robust than that from HT-29 cells despite Caco2 
cells having undetectable abundance of the 1α-OHase. Affinity of 25D relative to 1,25D was 
estimated by comparison of EC50 data. In HT-29 wildtype cells, the EC50 was 175-fold 
greater for 25D than for 1,25D, and for HT-29 CYP27B1em1Jgoff the difference was 174-fold. 
With Caco2 cells, the EC50 for 25D was 200-fold greater than that for 1,25D. These kinetic 
data demonstrate an independence of the 25D-mediated response from the expression of the 
1α-OHase, suggesting that 25D acts directly as a VDR agonist with lower affinity than 
1,25D.  
 
Discussion 
In the present study, we show that orally delivered 25D results in an upregulation of 
the vitamin D hormonal response in the duodenum of mice. This response was apparent with 
a dose of 100 pmol 25D and significant with a larger dose of 200 pmol 25D. Although we 
had used vitamin D-normal mice, we suspect that a vitamin D-deficient animal may exhibit 
increased sensitivity to 25D. This consideration is based on a previous study where the 
authors had observed an inverse relationship between the abundance of VDR in the prostate 
gland and serum [25D] in rats (5). If the abundance of VDR in the intestines also increases 
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during vitamin D-deficiency, then we would expect a lower dose of 25D to initiate 
transcriptional events. Given the high prevalence of vitamin D-deficiency and -insufficiency 
amongst industrialized nations (6), it may be necessary to further investigate the response to 
25D during altered vitamin D states to fully understand the importance of 25D in intestinal 
signaling.  
Our 0.1% FBS in vitro model has important relevance for examining the vitamin D 
hormonal response in the intestine. Other investigators have similarly removed FBS from 
media to study the activity of 25D (7–9); however, the physiological relevance is limited 
because internal organ systems generally rely on nourishment from blood containing DBP 
rather than from the digestive lumen where DBP would not likely be present or intact. 
Because we are focused only on the epithelium of the intestines, we feel that this model 
appropriately represents actions by vitamin D metabolites on the intestinal tissue. 
In vitro co-incubation with ketoconazole, a cytochrome P450 competitive inhibitor, 
did not inhibit the response to 25D. To our surprise, co-incubated HT-29 cells resulted in an 
unexpected increase in the 25D-mediated response. Our explanation for the increased 
response is because these cells constitutively express CYP24, the catabolic enzyme for both 
1,25D and 25D (10,11). As a cytochrome p450 enzyme, CYP24 is also a target of 
ketoconazole; therefore, we believe that our use of ketoconazole unintentionally, but 
effectively, inhibited CYP24 from catabolizing the 25D needed for full potential of the 
response. No such effect was observed with 1,25D, as we later found that the 100 nM 
treatment provided an excess of ligand for VDR activation. In contrast to HT-29 cells, Caco2 
cells express much less CYP24, and, indeed, the response to 25D was not affected by 
ketoconazole. Because ketoconazole did not inhibit responses for either cell line, we 
60 
knocked-down the expression of 1α-OHase in HT-29 cells. The resulting change in 
expression had no effect on the response to 25D either. Caco2 cells had even less abundance 
of CYP27B1 than did the HT-29 cells and elicited a remarkably similar response. These 
findings suggest that 25D is not dependent on CYP27B1 for VDR activation and that the 
substrate likely acts as a VDR agonist. Previous mechanistic studies have also demonstrated 
the agonistic activity of 25D by using knock-out models, inhibiting with ketoconazole or 
siRNA, and measuring cellular production of 1,25D (3,12–14). The important difference 
between our data and those of others is that our model system demonstrates cellular 
responses to 25D below physiological concentrations with relevance specifically to the 
intestine.  
Our dose-response data provides detailed characterization of the mechanism for the 
25D-mediated response. If we consider our initial hypothesis that 25D undergoes 1α-
hydroxylation prior to VDR activation, then we would have expected a two-step reaction for 
25D to elicit the same response as 1,25D. This two-step model would include hydroxylation 
by the 1α-OHase to form 1,25D (Step 1), followed by substrate binding to VDR (Step 2), and 
yielding activation of the hormonal response. The KM of the 1α-OHase (Step 1) has been 
previously determined to be 2.7 μM (15), whereas the Kd of 1,25D binding to VDR (Step 2) 
ranges from 0.13 to 1.2 nM (16–18), with one exception of 32 nM by Falsone and colleagues 
(19). Given these estimates, we note that the KM for the 1α-OHase is much greater than the 
Kd for VDR; therefore, we expect the hydroxylation of Step 1 to be rate-limiting with values 
on the order of 1 to 10 μM. Incredibly, our calculations of EC50 corresponds with the 
previous kinetic experiments. The EC50 values for 1,25D (0.16 ± 0.02 nM for HT-29 cells 
and 0.07± 0.01 nM for Caco2 cells) were similar to previous estimates of the Kd for VDR. 
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EC50 values for 25D (28 ± 9 nM for HT-29 cells and 16 ± 4 nM for Caco2 cells), on the other 
hand, were much less than expected for Step 1, the rate limiting step, and are within range of 
estimates for VDR binding. Binding affinity for 25D to VDR has not been calculated but has 
been estimated to be approximately 50- to 150-fold less than the affinity for 1,25D (14,19–
21). These estimates closely correspond to our relative affinity calculations of 175- and 200-
fold differences in relative affinity for HT-29 and Caco2, respectively. On the basis of data 
from the present study, our hypothesis for enteric 1,25D synthesis from 1-hydroxylation is 
not substantiated. Instead, we conclude that 25D in the intestinal lumen acts as a VDR-
agonist and activates the transcriptional response.  
Limitations of our in vitro investigations are important to consider. Although we 
demonstrated an effective model, our use of human colon adenocarcinoma cells may not 
precisely reflect the expression and responsiveness of in vivo duodenal cells for human and 
mouse. As a result, direct translation of our in vitro and in vivo data to human application 
may vary. 
Efforts to understand the effects of dietary 25D on the duodenum have received 
limited attention because the amount of 25D in foods is thought to be too low to impact 
serum [25D] (22,23). Egg yolks, for example, contain 25D ranging from 9.8 to 25 ng/g yolk 
(24,25). Meats vary from undetectable to 2.1 ng 25D/g of chicken breast (25–27), to 0.9 ng/g 
of beef (26–31) and to 0.6 ng/g of pork (28,32,33). Bovine milk also contains 25D in 
concentrations typically between 0.1 and 0.2 ng/mL (28,34). Estimations of 25D content in 
animal products correlate with the animal’s serum [25D] and can be increased by 
supplementation in the animal’s diet (25,29,33). Much of these animal-based food products 
offer as much 25D as, and sometimes more than non-hydroxylated vitamin D (27,32,35,36). 
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We argue that such small amounts of 25D may have substantial value when considered as a 
VDR-agonist with hormonal activity. If we consider a vitamin D-deficient mammal with 
increased VDR expression, then this nutritional source of 25D may have a physiological 
importance in maintaining health for the human or animal in times of insufficient sunlight 
when vitamin D is not endogenously made. The question that remains is if the hormonal 
activity of 25D will translate to increased calcium absorption. Some investigations have 
demonstrated such calcemic effects of 25D in the intestines (29,37,38), but the analyses 
assumed that 25D is converted to 1,25D by the kidneys before stimulating the intestine. In 
humans, for example, Vaes and colleagues gave healthy subjects 10 ug of 25D per day for 24 
weeks and observed decreases in serum parathyroid hormone that may reflect improvements 
in calcium homeostasis (39). These improvements are potentially caused by the hormonal 
activity of 25D itself, but the research group did not account for the potential agonist activity 
of 25D. Interestingly, we also have noted controversies that suggest diets low in animal 
protein have negative effects on bone calcification (40,41). Perhaps the differences can be 
attributed to the 25D present in the animal protein more-so than composition of the amino 
acids. More studies are needed to understand the full impact of dietary 25D. Our new 
perspective that orally administered 25D acts as a hormone itself adds important nutritive 
value to the small amounts of 25D present in animal-based foods that had not previously 
been considered.  
In conclusion, we found that oral consumption of 25D induces a vitamin D-response 
in the epithelial layer of the duodenum in mice. In addition, our in vitro analyses confirm that 
25D present in the lumen of the intestine acts as a VDR agonist to the intestinal epithelium.  
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Tables  
Table 4.1  Q-PCR primers synthesized by Integrated DNA Technologies. 
Gene1 Forward (5’-3’) Reverse (5’-3’) 
Mouse   
  Cyp24 CACACGCTGGCCTGGGACAC GGAGCTCCGTGACAGCAGCG 
  Gapdh GAAGGTCGGTGTGAACGGATT
TGGC 
TTGATGTTAGTGGGGTCTCGC
TCCTG 
Human   
  CYP24 CAGGTGCCACGGGCAGAAGA CCTGGATGTCGTATTTGCGGA
CAA 
  GAPDH CTTCTTTTGCGTCGCCAGCC GAGTTAAAAGCAGCCCTGGTG
A 
1. Cyp24/CYP24, cytochrome p450 family 24 subfamily A member 1; Gapdh/GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. 
 
 
Table 4.2  Parameters calculated from modified Michalis-Menten analysis of in vitro 
dose-responses to 1,25(OH)2D and 25(OH)D.1 
 HT-29  HT-29  Caco2 
 CYP27B1+ CYP27B1em1Jgoff CYP27B1+ 
1,25D    
    Emax (ddCT) 9.6 ± 0.2
a 9.0 ± 0.3a 10.6 ± 0.4d 
    EC50 (nM) 0.18 ± 0.01
b 0.23 ± 0.04b 0.07 ± 0.01 
25D    
    Emax (ddCT) 9.9 ± 0.8
a 9.6 ± 0.6a 10.6 ± 0.5d 
    EC50 (nM) 28 ± 9
c 40 ± 8c 16 ± 4 
Relative Affinity    
   25D/1,25D 175 174 200 
Values are mean ± SE. Common superscript letters are statistically similar (P > 0.05), as 
determined by F test comparison of best-fit lines. Emax, maximal effect; EC50, effective 
concentration at 50 percent response.  
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Figures 
 
 
Figure 4.1  Duodenal Cyp24 mRNA response to 25D and 1,25D in mice. (A) Q-PCR of 
Cyp24 expressed in duodenal tissue by control mice and by mice given oral 25D or 1,25D. 
Error bars represent mean ± standard error of the mean. *Significantly different from 
controls, P < 0.005. **Significantly different between groups, P < 0.05. (B) RISH of Cyp24 
in control mice, mice given 400 ng 25D and mice given 8 ng 1,25D. Hybridized mRNA is 
stained red as indicated by black arrows.  
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Figure 4.2  In vitro response to equimolar concentrations of vitamin D, 25D, and 
1,25(OH)2D with varying enrichments of FBS in treatment media. Responses are 
assessed by Q-PCR measurement of CYP24 mRNA. (A-C) Responses by HT-29 human 
cells. (D-F) Responses by Caco2 human cells. Values are relative to control run per each 
experiment. Error bars represent mean ± SEM. *Statistically different between groups as 
indicated.  
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Figure 4.3  Competitive inhibition of the 1α-hydroxylase had no effect on the 25D-
mediated response. Responses by (A) HT-29 and (B) Caco2 cells that were co-treated with 
25D or 1,25(OH)2D and 10 μM ketoconazole inhibitor or DMSO control. Responses are 
assessed by Q-PCR measurement of Cyp24a1 mRNA. Values are determined relative to 
control cell run simultaneously per each experiment. Error bars represent mean ± SEM. 
*Statistically different between groups as indicated.   
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Figure 4.4  Dose-response curves for 25D and 1,25D from HT-29 CYP27B1+, HT-29 
CYP27B1em1Jgoff, and Caco2 cells. (A) Western blot of CYP27B1 for each cell line. (B-E) 
Responses as measured by Q-PCR of Cyp24a1 mRNA and plotted by log-scale substrate 
concentration for (B,C) HT-29 and (D,E) Caco2 cells. Symbols represent mean ± SEM (n=3 
per symbol). Curves depict best-fit line from Michaelis-Menten analysis. Vertical lines 
represent calculated EC50 values. Y-axis tabs represents calculated Emax values. 
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CHAPTER 5.    THE ROLE OF 25-HYDROXYVITAMIN D-GLUCURONIC ACID 
ON COLON GENE EXPRESSION 
A manuscript intended to be published in a peer-reviewed journal. 
Carmen J. Reynolds1, Nicholas J. Koszewski2, Ronald L. Horst3, Donald C. Beitz1,  
and Jesse P. Goff2. 
Departments of Animal Science1 and Biomedical Sciences2, Iowa State University, Ames, IA 
50011. Heartland Assays2, Ames, IA 50010 
 
Abstract 
25-Hydroxyvitamin D3-3β-glucuronic acid (25D-Gluc) is present in human bile. Its 
secretion into the gut is thought to reach the colon, where bacterial enzymes cleave 
glucuronic acid conjugates and release free 25-hydroxyvitamin D (25D). This free 25D can  
act as a vitamin D receptor (VDR) agonist within the intestine and is hypothesized to elicit a 
VDR-mediated response in the colon. The activity of 25D-Gluc was investigated by 
measuring stimulation of VDR through increased expression of Cyp24 mRNA both in vitro 
and in vivo. Cell responses to 25D-Gluc were measured with and without bacterial 
glucuronidase and demonstrated that 25D-Gluc requires glucuronidase to elicit a full 
response. In vitamin D-sufficient mice, we tested oral and subcutaneous routes of 
administration and performed a surgical ligation experiment to assess mechanism of delivery. 
We found that both routes of administration of 25D-Gluc induced a VDR-mediated response 
in the colon, but not in the duodenum. When the intestine was ligated to block flow of 
digesta to the colon, neither oral nor subcutaneous administration of 25D-Gluc was able to 
stimulate the colon. These studies demonstrate the functional activity of 25D-Gluc after 
glucuronidase cleavage and in the colon. In addition, we showed that 25D-Gluc is delivered 
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to the colon via digestive passage. These findings offer evidence that 25D-Gluc participates 
in signaling from the liver to the colon and may be involved in VDR-mediated calcium 
absorption. 
 
Introduction 
The intestinal vitamin D receptor (VDR) mediates transcellular calcium absorption by 
increasing transcription of calcium channel and transport proteins. VDR is expressed in the 
colon (1–4), but the mechanism by which its preferred substrate, 1,25-dihydroxyvitamin D3 
(1,25D), stimulates VDR in the colon is unclear. Previous studies in our laboratory have 
shown that oral or subcutaneous administration of 1,25-dihydroxyvitamin D3-β-glucuronic 
acid (1,25D-Gluc) successfully delivers 1,25D to the colon and results in upregulation of 
VDR-mediated genes (5–7). This mechanism occurs because bacterial contents in the colon 
effectively cleaves the glucuronide moiety and liberates 1,25D. Unfortunately, in vivo 
production of 1,25D-Gluc only has been observed following intravenous administration of 
1,25D and, therefore, in vivo production of 1,25D-Gluc has uncertain physiological relevance 
(8–10). 
Recent investigations have shown that 25D-Gluc is synthesized by hepatic UDP-
glucuronosyltransferase 1A4 in humans and is present in both plasma and bile under 
unaltered conditions (11,12). On the basis of our research using 1,25D-Gluc, we predict that 
25D-Gluc also is cleaved in the colon by bacterial β-glucuronidase (GUS) to produce 
unmodified 25D. Emerging evidence has suggested that 25D can stimulate the VDR-
mediated response in the colon through local activation and/or agonistic action (Chapter 4; 
1,13–16). We hypothesize that 25D-Gluc, given orally or subcutaneously to mice, will be 
cleaved by bacterial GUS in the colon; then, the resulting 25D will elicit a hormonal response 
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there. To test this hypothesis, we first verified the activity of 25D-Gluc in vitro on colon cells 
with and without GUS. We then evaluated the VDR-mediated intestinal response in mice by 
administering 25D-Gluc both orally and subcutaneously. Lastly, we blocked passage of 
digesta beyond the small intestine by surgical ligation to discern if the mechanism of delivery 
requires that 25D-Gluc approach the colon via the digestive route. 
 
Methods 
Experimental reagents 
Vitamin D metabolites, 25D, 25D-Gluc, and 1,25D-Gluc, were used in cell culture 
and mouse studies. Both 25D (mol wt. 400.64) and 1,25D (mol wt. 416.64) were purchased 
lyophilized from Sigma Aldrich (St. Louis, MO, USA) and diluted with 100% ethanol. The 
glucuronide conjugates, 25D-Gluc (mol wt. 576.76) and 1,25D-Gluc (mol wt. 592.76), were 
synthesized from their respective metabolites by our laboratory using the Koenigs-Knorr 
reaction (17). Structural isomers of each glucuronide were separated by HPLC on a reverse-
phase column, and their structures were verified by mass spectrometry and NMR 
spectroscopy. Quantification of all vitamin D metabolites was performed by measuring the 
UV spectroscopy absorption at 245 nm wavelength and then calculated by using Beer’s law 
with the molar extinction coefficient of 18,300 mol-1L-1. Escherichia coli-derived GUS 
(76,717 U/ml) in 50% glycerol solution was purchased from Sigma Aldrich and diluted in 
0.01 M phosphate-buffered saline (PBS).  
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Tissue culture  
Two adherent human adenocarcinoma colon cells, HT-29 and Caco2 from the 
American Type Culture Collection (Manassas, VA, USA), were used to evaluate the 
response to 25D-Gluc. Cells were maintained at 37oC with 5% CO2 in Dulbecco’s Modified 
Eagle Medium (Gibco, Life Technologies, Grand Island, NY, USA) for HT-29 cells or 
Eagles Minimum Essential Medium (Corning Cellgro, Manassas, VA, USA) for Caco2 cells. 
Maintenance media were supplemented with 0.2% penicillin-streptomycin and 10% fetal 
bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA). Cells were split at 80% 
confluency and maintained up to passage 20. Experiments were performed in 6-well plates, 
seeded with 2x106 cells in 3 mL maintenance medium. Twenty-four hours after seeding, 
maintenance media were replaced with 3 mL low-serum media containing 0.1% FBS for 
treatment. For experimental treatments, 3 units of E. coli-derived GUS were added or an 
equal volume of sterile PBS vehicle and co-treated with 100 nM 25D, 100 nM 25D-Gluc, or 
an equal volume of 100 % EtOH vehicle (control). Each experimental plate contained one 
GUS control and one PBS control that were used to calculate the relative ddCT value for 
QPCR. The experiment was repeated, independently, three times (N = 3/treatment). 
Following a 16-hour treatment incubation time, the media were replaced with 500 μL Trizol 
Reagent (Invitrogen, Carlsbad, CA, USA) to suspend and lyse cells, and then stored at -80oC 
for RNA extraction.  
 
Animals 
Male C57BL/6 mice, 5-9 weeks old, were purchased from Charles River 
Laboratories. Mice were housed in solid-bottom ventilated cages maintained at constant 
temperatures (24-26oC) with a 12 hr light-dark cycle. Diets were standard rodent chow diet 
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containing 1% calcium and 1.5 IU/g vitamin D3 on an as-fed basis (Teklad 2014, Harland 
Laboratories, Madison, WI, USA) and were offered ad libitum. All animal handling, 
treatment and surgical procedures were approved by the Iowa State Institutional Animal Care 
and Use Committee. Mice were euthanized by inhalation of isoflurane followed by 
decapitation. Blood was collected from the cervical stump into heparinized microfuge tubes 
and then centrifuged to separate plasma. Mice then were dissected to remove a 3-5 cm 
section of proximal small intestine (duodenum) and of proximal colon. Dissected tissues 
were flushed with ice cold 0.9% sodium chloride saline solution and cut into 1 cm segments 
for tissue analyses. The first segment of the intestinal tissue was removed and discarded. The 
second cm was collected into Trizol Reagent, homogenized, and then stored at -80oC for total 
RNA isolation and QPCR. In some experiments, a third segment was fixed in neutral-
buffered formaldehyde for 24 hours, then transferred to 70% EtOH in RNase-free water for 
storage at room temperature.  
 
Animal experiments  
Acute oral dosing was used to evaluate the first-pass response by the intestine. Mice 
were given a single bolus of 1 nmol 25D-Gluc, 25 pmol 1,25D-Gluc (positive control), or an 
equal volume of ethanol (negative control). Experimental treatments were diluted in 50 uL 
peanut oil. Each treatment group consisted of five animals (N=5 per group). Mice were 
euthanized 4 hours after gavage and segments of the duodenum and colon were collected for 
both QPCR and RISH analyses.  
Acute subcutaneous dosing was used to evaluate function of biliary excretion. Mice 
were injected with 25D or 25D-Gluc at doses of 0.5, 1, and 2 nmol in 100 uL sterile 
propylene glycol. The mice were lightly anesthetized with isoflurane to ensure accurate 
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subcutaneous delivery. Control mice received subcutaneous injection of carrier alone. Four 
animals were treated per dose (N= 4/dose). Mice were euthanized 8 hours after receiving the 
subcutaneous injection to collect both duodenal and colon tissue segments for QPCR 
analysis. 
Surgical Ligation was used to prevent vitamin D from reaching the colon. In intestinal 
ligation experiment, mice were subjected to either surgical ligation or sham surgery before 
receiving 25D or 25D-Gluc delivered either orally or subcutaneously. Mice were 
anesthetized by inhalation of isoflurane and injected with 200 μL of 0.075% bupivacaine 
subcutaneously into muscle tissue on both sides of the abdomen for local 
anesthesia/analgesia. A 2 cm midline incision was made into the abdomen. A section of small 
intestine was exteriorized, and a suture was placed around the section of intestine and tied 
tightly to block flow of digesta. Care was taken to reduce interruption of blood flow to the 
intestine. In some animals the cecum was also exteriorized and 25D-Gluc in propylene glycol 
was injected into the lumen of the cecum using a 26 g needle inserted at a 45o angle. The 
intestine and cecum were returned to the peritoneal cavity and the abdomen and skin closed 
in a single layer of suture. Sham surgical animals underwent the same anesthesia and midline 
incision. A segment of the small intestine was exteriorized, but the segment of intestine was 
not ligated before being returned to the peritoneal cavity and the incision closed. Following 
surgery, animals received either a subcutaneous injection (when anesthetized) of 2 nmol of 
25D, 25D-Gluc, or EtOH carried in 100 uL propylene glycol or an oral gavage (when fully 
conscious and able to swallow at about 15 to 20 minute post-surgery) of 2 nmol 25D, 25D-
Gluc, or EtOH carried in 100 μL peanut or corn oil. Each treatment group included 4-8 mice  
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for each procedure. Eight hours after receiving their respective treatment, the mice were 
euthanized, as described above, and both the duodenum and colon were collected for QPCR 
analysis. 
 
RNA isolation 
Total RNA was separated from cell and tissue extracts by Trizol-chloroform 
separation and then passed through the RNeasy Mini Prep column (Qiagen, Germantown, 
MD, USA) as previously described (Chapters 3, 4). In short, chloroform was added to the 
Trizol homogenate and centrifuged. The upper layer was diluted in ethanol and transferred to 
the RNeasy column. The column was washed with buffer in accordance with manufacturer’s 
protocol, with an added sodium-potassium wash step. RNA was eluted by RNase-free water, 
measured by UV absorbance at 260 nm and the 260/280 ratio, and then diluted to 0.5 ug 
RNA/uL. RNA (1μg) was used as template for cDNA synthesis by Superscript III First 
Strand Synthesis (Invitrogen). cDNA was diluted with buffer (10 mM Tris and 1 mM EDTA 
in RNase-free water) to 60 uL for cell culture and 100 uL for tissue samples and stored at -
20oC. 
 
Q-PCR  
Messenger RNA was analyzed by QPCR with glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) and cytochrome P450 family 24 subfamily A1 (Cyp24) target probes 
for both human and mouse as previously described (Table 4.1). Briefly, Quanta SYBR Green 
(QuantaBio, Beverly, MA, USA) was used to detect targets on a CFX96 C1000 thermocycler 
(Bio-Rad Hercules, CA, USA). Cyp24 was used as a measure of the VDR-mediated response 
as it has previously been shown to rapidly and robustly increase expression upon ligand 
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binding and activation of VDR (18). Gapdh was used to calculate dCT for normalizing CT of 
Cyp24. In cell culture, the respective experimental control was used to calculate relative 
ddCT, whereas in mouse experiments the average dCT of control animals was used to 
calculate relative ddCT. 
 
RNA in situ hybridization  
Formalin-fixed tissues were used for RISH of Cyp24 mRNA. Tissues were paraffin-
embedded, and then sectioned at 5 μm thickness. Immediately after sectioning, tissues were 
hybridized with RNAscope 2.0 HD Red Manual Detection Kit (ACDbio, Newark, CA, USA) 
by using probes for Cyp24 (sequence proprietary to ACDbio) and counterstained with 
hematoxylin. Images were obtained by a light microscopy at 20x magnification, and mRNA 
is detected in red chromogenic dye.  
 
Statistical analyses 
Statistical analyses were performed by GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA). Analyses include 1-way ANOVA comparisons with Tukey adjustments 
for pairwise comparison and t-tests, as indicated, to directly compare effects between two 
specific groups. Statistical significance was notated when P < 0.05.  
 
Results 
In vitro response to 25D and 25D-Gluc 
Bacterial GUS enabled the VDR-mediated response to 25D-Gluc in cultured HT-29 
and Caco2 human colon adenocarcinoma cells. Both cell lines demonstrated robust VDR-
mediated responses when incubated with 100 nM 25D in low-serum conditions (Figure 5.1). 
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The response with 25D was not affected by GUS. Equimolar incubation with 25D-Gluc 
produced only a small increase in Cyp24 mRNA that was significant in Caco2 cells (6.2 ± 
0.1 ddCT, P <0.0001), but not significant in HT-29 cells (1.3 ± 0.5 ddCT, P = 0.1; statistical 
analysis performed on dCT values, data not shown). Co-treatment of 25D-Gluc with GUS 
enabled robust responses that were over 32-fold greater than without GUS for both cell lines. 
For HT-29 cells, the response to 25D-Gluc with GUS was statistically similar to the 
equimolar 25D treatments. Based on these data, it is reasonable to consider that cells or the 
cell media have limited intrinsic GUS activity; yet, the glucuronide moiety largely interferes 
with cellular uptake and/or VDR activation. Such dependence on GUS would imply that the 
conjugated 25D would have limited biologically activity until reaching the cecum or colon, 
where GUS activity is abundant (19,20). 
 
Intestinal responses to oral vitamin D glucuronides in mice 
Oral administration of either 25D-Gluc or 1,25D-Gluc elicited transcriptional 
responses in the colon with no effect apparent in the duodenum. After 4 hours, 1 nmol of 
25D-Gluc induced expression of Cyp24 mRNA (5.3 ± 1 ddCT, P =0.007) that was 
statistically similar to the response to 1,25D-Gluc (25 pmol, 7.8 ± 0.3 ddCT, P= 0.06; 
Figures 5.2A,B). Localization of Cyp24 mRNA by RISH demonstrates that the response 
appears in the epithelial cells of the colon and not the submucosal, muscularis, or lymph 
regions (Figure 5.2C). Furthermore, no Cyp24 mRNA was observed in crypt regions of the 
colon. These data confirm that the glucuronide moiety has insignificant biological activity in 
the duodenum where little or no bacterial GUS is present and, instead, functions exclusively 
in the colon where the glucuronide is cleaved to liberate 25D. 
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Intestinal responses to subcutaneous administration of 25D and 25D-Gluc in mice 
 
Because 25D-Gluc is present in blood and bile (11), we decided to evaluate the 
effects of 25D-Gluc when administered subcutaneously. We found that when given by this 
route, 25D-Gluc still elicits a significant response in the colon of mice, but no increase in 
Cyp24 occurs in the duodenum (Figure 5.3). This 8-hour response was dose-dependent, with 
1 nmol 25D-Gluc (1.7 ±0.6 ddCT, P = 0.04) and 2 nmol 25D-Gluc (3.1 ± 0.9 ddCT, P =0.02) 
achieving statistical significance from control animals. Conversely, equimolar treatment with 
25D elicited a response in the duodenum from only the 2 nmol dose with no effect on the 
colon. The data for subcutaneous 25D-Gluc are in agreement with observations made from 
oral treatments. 
 
 Effects of intestinal ligation on responses to 25D  
 
Surgical ligation of the small intestine physically blocks passage of digesta and bile to 
the distal intestine. The ligation procedure itself caused no changes in Cyp24 expression 
compared to the sham procedure in both the duodenum and colon (Figures 5.4A,D). Oral 
delivery of 25D caused increases in Cyp24 mRNA in the duodenum following both the sham 
(2.2 ± 0.7 ddCT) and the ligation procedures (3.7 ± 1.4 ddCT) with no difference between 
procedures (P = 0.4). The colon exhibited a slight increase in Cyp24 from oral 25D following 
the sham surgery (0.9 ± 0.2 ddCT; P = 0.01), but not following ligation surgery (0.4 ± 0.5 
ddCT) suggesting that the oral 25D moved to the colon via intestinal passage and was 
blocked by the surgical ligation. Subcutaneous administration of 25D had no effect on the 
duodenum or colon from either surgery. These data do not agree with our duodenal 
observations in the non-surgical model that had demonstrated a significant increase in Cyp24 
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mRNA with 2 nmol subcutaneous 25D (Figure 5.3). It is possible that passage of 25D into 
the intestinal tract was impaired following the surgery. Regardless, the data collected suggest 
that intestinal stimulation from 25D must occur from inside the intestinal tract. 
 
Effects of intestinal ligation on responses to 25D-Gluc  
Oral delivery of 25D-Gluc successfully increased Cyp24 expression in the colon 
following the sham surgery compared to controls (4.6 ± 1.4 ddCT, P = 0.01; Figure 5.4F). 
When ligated, however, the VDR-response in the colon was completely abolished (-0.4 ± 0.3 
ddCT; P = 0.007). Similarly, subcutaneous administration of 25D-Gluc induced a small 
response (1.8 ± 0.7 ddCT, P = 0.09) that was completely abolished following surgical 
ligation (-0.3 ± 0.2 ddCT; P = 0.049). It is important to note that the subcutaneous 25D-Gluc 
affected the intestines, whereas the equimolar subcutaneous 25D did not, suggesting that 
liver function was intact. To ensure that the colon was not impaired following ligation, we 
also injected 25D-Gluc directly into the cecum at the time of the surgery and euthanized 
these mice 4-8 hours later. Mice with cecum injections did exhibit increased expression of 
Cyp24 mRNA (6.4 ± 2.1 ddCT; P = 0.02) to a similar extent as oral 25D-Gluc with a sham 
surgery (P = 0.5). No responses appeared in the duodenum for any 25D-Gluc treatment 
combination and reiterates the concept that the glucuronide moiety disables the activity of 
25D until removed by bacterial GUS. The responses with surgical ligation did, indeed, 
confirm that 25D-Gluc specifically targets the colon and that it does so via intestinal passage. 
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Discussion 
It is well-accepted that the renal hormone 1,25D targets the enterocytes of the 
duodenum to increase the capacity of calcium absorption. However, the glucuronide-
conjugated form of 1,25D activates VDR in the colon, rather than the duodenum (5,6). In 
Chapter 4, we showed that 25D can stimulate the duodenum through agonistic binding and 
activation of VDR; thus, we hypothesized that 25D-Gluc would stimulate the colon. In the 
present study we found that 1 nmol 25D-Gluc, given orally or subcutaneously, induced the 
VDR-mediated response precisely in the colon. Interestingly, 25D required a larger dose than 
25D-Gluc to stimulate the duodenum when given subcutaneously; however, we question if  
the low response was caused by actual differences in intestinal responses or by an artifact of 
suboptimal timing. The responses by 25D-Gluc would imply that it, too, functions as a VDR 
agonist in the colon.  
The action of 1,25D on the enterocytes of the intestine is generally believed to occur 
via the blood stream. In the case of the colon, this pathway would imply that 1,25D crosses 
the basolateral membrane of enterocytes to bind to VDR and elicit its transcriptional 
response. Surgical ligation of the intestine interferes with movement of digesta and bile to the 
colon and has been used to demonstrate that 1,25D-Gluc stimulates the colon via digestive 
passage (6). In the present study, we found that surgical ligation also interferes with transit of 
oral 25D and 25D-Gluc, and subcutaneous 25D-Gluc by completely preventing VDR-
stimulation in the colon. These data suggest that both 25D and 25D-Gluc are only active to 
the intestine when delivered via digesta or digestive secretions. 
The likely explanation for our results is that 25D-Gluc has no activity until 
encountered by bacteria in the distal intestine. In a previous investigation, we had 
demonstrated that intestinal contents obtained from rat colons have sufficient bacterial 
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activity to cleave the glucuronide from 1,25D-Gluc and liberate 1,25D (5). Evidently, colon 
bacteria produce ample amounts of GUS that are specific for beta-linked sugars (5,19–21). In 
our in vitro assays, we verified that the 25D-Gluc had little activity until co-treated with 
bacterial-derived GUS that cleaves the glucuronic acid. While some activity of 25D-Gluc 
was evident, no such response was observed in the duodenum, even when surgical ligation 
would presumably stall 25D-Gluc proximal to the ligation site and within the small 
intestines. The role of the bacterial GUS justifyies the specificity of 25D-Gluc for the colon 
that we have observed.  
Because of its natural presence in bile, 25D-Gluc may have a physiological role as a 
signaling molecule to the colon. The application of enterohepatic circulation for vitamin D 
glucuronides had been proposed by Kumar and colleagues (22,23). Shortly thereafter, these 
conjugated metabolites were considered to lack sufficient biological activity and were 
described as waste products for removing excessive amounts of vitamin D metabolites (24–
28). However, those studies focused on the calcemic activities within the duodenum, whereas 
we have demonstrated the target to be in the colon. The notion that vitamin D glucuronides 
affect the colon rather than the duodenum has renewed interest in the enterohepatic 
circulation hypothesis. A model proposed by Gao et al., describes enterohepatic transport for 
the glucuronide conjugate of 25D that assumes liberated 25D is activated by enteric 1α-
hydroxylase, providing 1,25D for local action in the colon (12). Because liberated 25D acts 
as a VDR agonist, we propose a revised model of enterohepatic signaling that is entirely 
independent of local 1,25D production. This model suggests that calcium absorption is partly 
managed by the liver, whereas internal calcium distribution and utilization remains fully 
dependent on the renal production of 1,25D. Active calcium transport by the intestine has 
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been studied primarily for the duodenum, yet the colon has also been recognized to be able to 
absorb calcium in a vitamin D-dependent manner itself (29–32). Genetic studies on 
expression of VDR in the distal intestines of mice provide additional support for the role of 
the colon in intestinal calcium absorption (33–35). While we have not directly measured 
changes in colon calcium absorption, we believe that 25D-Gluc-mediated VDR activation in 
the colon has the potential to increase calcium absorption as well. Additional investigations 
on this function of 25D-Gluc are necessary to better understand the regulation of colon 
calcium absorption by enterohepatic signaling.  
Our in vivo studies were performed on vitamin D-sufficient mice that consume a diet 
that meets the Association of American Feed Control Officials standards for vitamin D and 
calcium content in rodent diets. Humans, particularly in the United States, tend to have lower 
circulating 25D concentrations and consume a recommended diet that is proportionally lower 
than the minimal standards for rodent diets. Furthermore, our data focused only on the 
expression of Cyp24 as an indicator of the VDR-mediated response, but the data does not 
investigate expression and abundance of other VDR-mediated proteins involved in calcium 
absorption.  
In conclusion, we have identified the physiological target of 25D-Gluc to be the 
colon. Our data demonstrates that 25D-Gluc is transported to the colon via digesta to be 
cleaved by bacterial enzymes into free 25D. The free 25D then act as a VDR agonist there 
within the colon. We believe that this mechanism of enterohepatic signaling may be an 
important factor in maintaining calcium absorption by the colon.   
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Figures 
 
 
Figure 5.1  Bacterial GUS enables aides in the 25D-Gluc-mediated response. In vitro 
assessment of 25D-Gluc with bacterial GUS (N=3/group) by HT-29 (A) and Caco2 (B) cells. 
Treatment was with 100 nM concentrations of 25D or 25D-Gluc and co-treatment was with 1 
U/mL E. coli GUS or PBS in low-serum conditions. Values are normalized to GAPDH and 
relative to respective experimental EtOH-treated controls (not shown). Bars are mean ± SEM. 
*Significantly different or astatistically similar by ANOVA pairwise comparisons of ddCT 
values. 
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Figure 5.2  The effects of oral administration of 1 nmol 25D-Gluc or 25 pmol 1,25D-
Gluc on the expression of Cyp24 in the intestines of mice 4 hours after administration. 
(A) Q-PCR of duodenal and colon tissues, values (ddCT) are normalized to Gapdh and 
relative to the average of control tissues. Bars represent Mean ± SEM. *Statistically different 
from control (P <0.01). (C) Representative images of RISH for Cyp24 mRNA, indicated by 
red stain with hematoxylin counterstain. 
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Figure 5.3  Subcutaneous administration of 25D and 25D-Gluc stimulates increased 
expression of Cyp24 in the intestine in 8 hours. The duodenum is stimulated by 25D, 
whereas the colon is only stimulated by the glucuronide. Values (ddCt) are normalized to 
Gapdh and relative to the average of controls. Bars are mean ± SEM with N=4 per group. 
*Statistically different from control or between groups as indicated, P <0.05. 
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Figure 5.4 Effects of surgical ligation on the responses to 25D and 25D-Gluc. Ligation of 
the intestine interfered with the activity of 25D-Gluc in the colon. Values (ddCt) are 
normalized to Gapdh and relative to the average of combined controls. Bars are mean ± SEM 
with N =5-8 mice per group. *Statistically different from control or as indicated by t-test 
comparison (P<0.05). **Statistically different from control or as indicated by ANOVA 
analysis (P<0.05). 
 
Control
Sham Ligation
-2
0
2
4
6
8
10
C
y
p
2
4
 d
d
C
T
25D-Gluc
-2
0
2
4
6
8
10
*
**
**
**
Oral SubQ Cecum
*
C
y
p
2
4
 d
d
C
T
25D
-2
0
2
4
6
8
10
*
Oral SubQ
C
y
p
2
4
 d
d
C
T
Control
Sham Ligation
-2
0
2
4
6
8
10
C
y
p
2
4
 d
d
C
T
25D
-2
0
2
4
6
8
10
Oral SubQ
**
**
C
y
p
2
4
 d
d
C
T
25D-Gluc
-2
0
2
4
6
8
10
Oral SubQ Cecum
Sham
Ligation
C
y
p
2
4
 d
d
C
T
Duodenum
Colon
A B C
D E F
93 
CHAPTER 6.    GENERAL CONCLUSION 
Overall Summary and Conclusions 
Vitamin D has a powerful impact on intestinal calcium absorption. Since the 
discovery of 1,25D, calcium activities throughout the body were attributed to the hormone’s 
actions. Research from the present dissertation challenges our current theories by providing 
an alternate mechanism of intestinal stimulation through the agonistic action of 25D, rather 
than 1,25D. We began in Chapter 3 by using the RNAscope assay to show that 1,25D and its 
glucuronide-conjugate both stimulate VDR in the intestinal epithelium nearest the center of 
the lumen. This observation was key to the realization that 25D may elicit a response inside 
the intestine where denatured DBP or albumin would not bind to and sequester the substrate. 
Then, in Chapter 4, we evaluated the activity of oral 25D in the intestines and the mechanism 
driving its action. In the mouse duodenum, we found that just 200 pmol of orally 
administered 25D significantly upregulated the VDR-mediated response. By using in vitro 
inhibition and knockdown assays in low-serum culture media, we determined that 25D 
functions as an agonist and does not require hydroxylation. The agonistic action of 25D has 
been demonstrated previously; however, those studies either used supraphysiological 
concentrations of 25D or did not have a physiological application to their low-serum in vitro 
models (1–4). Furthermore, by using our kinetics-based approach with in vitro dose-
responses of 1,25D and 25D, we estimated that 25D has a 175- to 200-fold lesser affinity to 
VDR than does 1,25D, which corresponds with previous estimates (1,5–7). In Chapter 5, we 
merged the concepts we had acquired from RNAscope of the colon with 1,25D-Gluc 
(Chapter 3) and the agonistic action of 25D within the duodenum (Chapter 4). The resulting 
idea was that 25D-Gluc would function as an agonist in the colon. As anticipated, the colon, 
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and not the duodenum, responded to 1 nmol of 25D-Gluc both orally and subcutaneously in 
an action that was dependent on bacterial cleavage of the glucuronide moiety. Taken 
together, these studies demonstrate how 25D, and its glucuronide-conjugate, have roles in 
regulating the VDR-mediated response in the duodenum and colon, respectively. 
Current literature describes the point of entry for 1,25D into the intestines at the 
serosal or basolateral membrane of the enterocyte (8–12). In studies from our laboratory, we 
have identified incongruities suggesting that stimulation, instead, occurs at the apical 
membrane via digestive passage. Studies from Koszewski et al., found that increases in 
serum 1,25D concentration did not always correlate with induction of a VDR-mediated 
response in the colon (13). In Chapter 3 we noted a similar finding, such that oral 1,25D-
Gluc greatly increased concentrations of serum 1,25D, but the increase had no effect on 
duodenal VDR-mediated gene expression. In experiments by the Goff laboratory, we 
performed intestinal ligations in mice that blocked passage of digesta to the distal region to 
experimental test the point of entry. If the current theory were true, then ligating the intestine 
would have no effect on the responses; however, we have found that ligation completely 
abolished distal responses with 25D (oral) and 25D-Gluc (oral and subcutaneous). Together, 
these findings reiterate the concept that the intestine is not regulated by the endocrinal 
circulation of 1,25D. These data dispute the argument that renal 1,25D regulates intestinal 
calcium absorption and, instead, propose a hypothesis that hepatic release of vitamin D 
metabolites may be the preferred mode of stimulating the intestine. 
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From the present dissertation, we have formulated two new perspectives on vitamin 
D-mediated calcium absorption in the intestine. The first is that 25D, consumed orally or 
excreted by the liver, stimulates VDR primarily at the duodenum. The second is that the 
hepatic synthesis of 25D-Gluc stimulates VDR at the colon. Both perspectives eliminate the 
dependence on renal or enteric 1,25D synthesis, although they do not omit the possibility that 
1,25D may also participate through the same mechanism. 
 
Strengths and Limitations 
 The primary strength of this dissertation is its cohesive progression of data. Each 
article creates a stand-alone statement and provides essential data for the following article. 
For example, Chapter 3 introduces the RNAscope RISH technique that is presented again in 
Chapters 4 and 5. In another example, Chapter 4 describes the mechanism of action for 25D 
activity in the duodenum that was fundamental to understanding the physiological function 
and application of 25D-Gluc in the colon. Aside from the coordinating themes throughout the 
dissertation, an additional strength was the use of both mouse and human cell culture to 
augment and substantiate the findings.  
The major limitations of this research can be summarized with three items: (1) 
money, (2) time, and (3) knowing if our conclusions translate to human nutrition and disease. 
Money and time share similarities such that both create limits to research despite creatively 
constructed hypotheses and detailed experimental design. Such constraints also limited much 
of the experimental focus to only Cyp24 mRNA assessments because other VDR-mediated 
proteins are optimally upregulated at later timepoints and would require additional internet  
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submissions of Institutional Animal Care and Use Committee protocols as well as 
appropriate funds. Human application is the ultimate goal in our research; however, human 
subjects are difficult for experimentation for both cooperativity and cost.   
 
Proposed Applications of Research 
Implications of 25D in the diet 
There is an ongoing argument that protein consumption is important for bone strength 
and/or development (14). Reviews of the literature are controversial in that some identify an 
association of protein intake and bone health whereas others cannot (15,16). The factor we 
are concerned with is where the dietary protein is derived. Interestingly, studies that do show 
correlation use animal protein sources (ie meat, diary, or eggs), rather than isolated protein 
supplements (17,18). Because of its intrinsic significance, 25D has a natural presence in 
animal-based food products. Egg yolks, for example, contain 25D ranging from 9.8 to 25 
ng/g yolk (19,20). Meats vary from undetectable to 2.1 ng/g 25D/g of chicken breast (20–22), 
to 0.9 ng/g of beef (21–26), and to 0.6 ng/g of pork (23,27,28). Bovine milk also contains 
25D in concentrations typically between 0.1 and 0.2 ng/mL (23,29). These estimations 
correlate with the animal’s serum [25D] and can increase by supplementation in the diet 
(20,24,28). The quantity of 25D in animal-based foods is notable, offering as much as and 
sometimes more than non-metabolized vitamin D (22,27,30,31). By importing the concept 
that 25D acts as an agonist and induces a response in the intestine, then we can hypothesize 
that the improvements from dietary protein can be attributed to the 25D content of the food 
item more-so than the amino acid content. This viewpoint could justify the dynamic variation  
  
97 
and inconsistencies in research among diets using animal-based protein. We believe that a 
diet incorporating animal protein would also supply 25D not otherwise accounted for, and, 
therefore, have beneficial effects on calcium uptake and greater bone health. 
 
Seasonal importance of 25D 
The seasonal effects of vitamin D in humans and many other organisms is well 
described. In the summer, sunlight provides the energy to induce vitamin D3 synthesis in the 
skin, leading to adequate amounts of 25D in circulation. Humans and animals would 
consume a diet that may be higher in plants because of the seasonal availability. In winter 
months, particularly further from the equator, UVB light waves from the sun become less 
effective and are less able to maintain adequate vitamin D3 synthesis (32). In addition, 
vegetation becomes sparse and omnivorous humans and animals would then turn to 
consumption of animal protein. This animal protein diet would contain enough 25D to 
maintain calcium absorption throughout the winter season and prevent wasting of calcium 
from bones. Additional research would need to be conducted to fully understand the impact 
of dietary 25D on calcium homeostasis and management.  
 
The entero-hepatic circulation of 25D-gluc 
The entero-hepatic circulation of vitamin D has been previously described in an early 
proposal by Kumar et al. and Weisner et al., and a more recent rendition by Gao et al. (33–
35). The evidence provided in the present dissertation largely supports these hypotheses, yet 
provides additional specificities not previously considered. Kumar et al. and Weisner et al. 
had suggested that metabolites of 1,25D, mostly the glucuronide conjugate, are secreted into 
bile by the liver, then are reabsorbed in the duodenum. However, biological activity of the 
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glucuronide metabolites was deemed ineffective, thus Kumar and colleagues did not further 
pursue the functional aspect of 1,25D in enterohepatic circulation. Nearly 40 years later, Gao 
et al. re-introduced enterohepatic circulation of vitamin D metabolites. Instead of 1,25D-
Gluc, Gao et al. described the enterohepatic cycle based on 25D-Gluc, which his research 
group had also confirmed in human plasma and bile (36). In addition, the newer proposal 
focused on the action of glucuronides in the colon following bacterial glucuronidase activity, 
which had been suggested by Goff and colleagues (13,37). Gao et al.proposed that the 25D, 
resulting from the cleavage of 25D-Gluc, acts as a substrate for enteric 1α-hydroxylase to 
locally synthesize 1,25D. On the basis of the evidence we provided, we believe that 25D-
Gluc is secreted intentionally to provide 25D in the colon as a hormonal agonist. As a result, 
our version of model describes a hepatic signaling mechanism, rather than enterohepatic 
recycling. 
The hepatic signaling of 25D-Gluc model explains inconsistencies in 1,25D and 
impaired calcium absorption. A particularly intriguing example is the Roux-en-Y gastric 
bypass surgery. It is apparent that following the surgery, increases in 1,25D cannot produce 
increased calcium absorption (38–41). After 5 years, the calcium deficiencies increase risks 
for metabolic bone diseases in these patients (42–44). We believe that the impairments in 
calcium absorption are a result of the altered bile metabolism. These alterations perturb 
enterohepatic circulation of bile and appear to be recycling bile acids prior to entry into the 
colon (45). If our hypothesis that the liver secretes 25D-Gluc to maintain calcium absorption 
is correct, then we could fully explain the loss of calcium absorption following Roux-en-Y 
gastric bypass surgery. Such explanation could improve management strategies and minimize 
risks for bone diseases following the surgery. 
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Future Research 
The potential regulation of intestinal calcium absorption by 25D and 25D-Gluc is 
clearly evident based on the present dissertation. However, future research is required to 
verify that 25D-mediated activation of VDR results in increased calcium absorption, to 
determine the effective doses in humans, and lastly, to describe the regulation of 25D-Gluc 
synthesis and secretion by the liver. It is possible that this research will greatly contribute to 
the understanding of vitamin D and calcium absorption in the near future 
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